Datasets:
w139700701
/
TheraSAbDab_IgFold

Dataset card Data Studio Files Community
1
Search is not available for this dataset
Therapeutic
stringlengths
8
15
Format
stringlengths
3
52
CH1 Isotype
stringclasses
15 values
VD LC
stringclasses
9 values
Highest_Clin_Trial (Oct '21)
stringclasses
12 values
Est. Status
stringclasses
4 values
Heavy Sequence
stringlengths
2
132
Light Sequence
stringlengths
2
113
Heavy Sequence (if bispec)
stringlengths
2
132
Light Sequence (if bispec)
stringlengths
2
112
100% SI Structure
stringlengths
7
224
⌀
99% SI Structure
stringlengths
7
364
⌀
95-98% SI Structure
stringlengths
7
207
⌀
Year Proposed
int64
1.99k
2.02k
Year Recommended
stringclasses
30 values
Target
stringlengths
2
75
Companies
stringlengths
2
1.7k
Conditions Approved
stringlengths
2
277
Conditions Active
stringlengths
2
910
Conditions Discontinued
stringlengths
2
384
⌀
Development Tech
stringlengths
2
149
Notes
stringlengths
8
194
⌀
Heavy Sequence second
stringlengths
127
158
⌀
Light Sequence second
stringlengths
116
136
⌀
Abagovomab
Whole mAb
G1
Kappa
Phase-III
Discontinued
QVKLQESGAELARPGASVKLSCKASGYTFTNYWMQWVKQRPGQGLDWIGAIYPGDGNTRYTHKFKGKATLTADKSSSTAYMQLSSLASEDSGVYYCARGEGNYAWFAYWGQGTTVTVSS
DIELTQSPASLSASVGETVTITCQASENIYSYLAWHQQKQGKSPQLLVYNAKTLAGGVSSRFSGSGSGTHFSLKIKSLQPEDFGIYYCQHHYGILPTFGGGTKLEIK
na
na
null
null
null
2,006
2007
CA125
Menarini
na
na
Ovarian cancer;Pancreatic cancer
na
null
Q VKLQ ESGA ELA RPGA SVKLSCK ASGY TFTNYWMQWVK QRPGQGLD WIGAI YPGDGNT RYTHKF KG KATLTA DKSSST AYMQLSS LASEDSG VYYCA RGEGN YAWFAYW GQGT TVTVS S
DI ELT QSPA SLSA SVGE TVTITCQ ASEN IYSYLAWHQ QKQGKSP QLLVYN AK T LAGG VSSRF SGSGSGT HFSLKIKS LQPEDF GIYYCQ HHYG IL PTFGGGT KLEI K
Abciximab
Fab
G1
Kappa
Approved
NFD
EVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSA
EIVLTQSPVTLSVTPGDSVSLSCRASRDISNNLHWFQQTSHESPRLLIKYASQSMSGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQTNSWPYTFGGGTKLEIK
na
na
6v4p:CD
null
null
1,993
1994
CD41_CD61
Janssen Biologics BV;Eli Lilly
Coronary artery restenosis;Unstable angina pectoris
na
Arterial occlusive disorders;Myocardial infarction;Stroke
na
Sequence sourced through DrugBank.
EV QLQ QSG TVLA RPGA SVKMSCE ASGY TFTNYWMHWVK QRPGQGL EWIGAI YPGNSDTS YIQKF KGK AKLTAVT STT SVYMELS SLTNEDS AVYYCTL YDG YYVFAYW GQG TLVTVS A
E IVLT QSP VTLSV TPGD SVSLSCRA SRDISNNL HWFQQ TSHESP RLLIKYA SQSMSGIPS R FSGSGSGT DFTLSINSV ETEDF GMYFCQ QTNSWP YT FGGG TKLEI K
Abelacimab
Whole mAb
G1
Lambda
Phase-III
Active
QVQLLESGGGLVQPGGSLRLSCAASGFTFSTAAMSWVRQAPGKGLEWVSGISGSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARELSYLYSGYYFDYWGQGTLVTVSS
QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNDVSWYQQLPGTAPKLLIYKNYNRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCSAWDQRQFDVVFGGGTKLTVL
na
na
null
null
6r8x:CB
2,018
2019
F11
Novartis;Anthos Therapeutics;Labcorp Drug Development;TIMI Study Group
na
Venous Thromboembolism; Stroke;Thrombosis
na
na
(Feb '22) Added in missing residues 97 and 98. (Jun '22) Added missing residues at start of VL CDR3.
Q VQLLES GGG LV QPGG SLRLSC AASGF TFST A A MSWVR QAPGKGL EWVS GISGSGSS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARELSY LY SG YYFD YWGQG TLVTV SS
QSVLTQPPSASGTPGQ RVTISC SGSSSNIGSNDV SWYQ QLPGTAP KLLIYK NYNRPSGVPDRFSGSKSGTS A SLAI SGLQSEDEAD YYCS AWDQRQF DVVF GGGT KLTV L
Abituzumab
Whole mAb
G2
Kappa
Phase-II
Active
QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK
na
na
null
null
null
2,013
2014
ITGAV
Merck
na
Colorectal cancer;Systemic scleroderma
Ovarian cancer;Prostate cancer;Solid tumours
na
4o02 claims to be abituzumab (17E6), but is not
Q VQLQQ SGGE L AKPGA SVKVSCK ASGY TFSSFWMHWVR QAPGQG LEWIGYI NPRSGYTEYN EIF RDKA TMTT DTSTS TAYMELS SLRSEDT AVYYCASFL GRGAMDYWGQG TTVTVS S
DIQ MT QSPSS LSA SVGD RVTITCR ASQD ISNYLAWYQ QKPGKAP KLLIYYT SKIHSGVPSRFSGSGSGTD YTFTIS SLQ PEDIA TYYC QQGNTFP YT FGQGT KVEI K
Abrezekimab
Fab
G1
Kappa
Phase-I
Discontinued
QVTLKESGPVLVKPTETLTLTCTVSGFSLTNYHVQWIRQPPGKALEWLGVMWSDGDTSFNSVLKSRLTISRDTSKSQVVLTMTNMDPVDTATYYCARDGTIAAMDYFDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCLASEDISNYLAWYQQKPGKAPKLLIYHTSRLQDGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYRFPLTFGGGTKVEIK
na
na
null
null
null
2,017
2018
IL13
UCB
na
na
Asthma
na
(Jun '22) Added missing FWH3 and CDRL3 residues
QV TLK ESGP VLV KPTE TLTLTCTV SGF S LT NYHVQWIR QPPGKA LEWLGVMW SDGDTSFN SVLKSRLTIS RDTSKS QVVLTMT NMDPVDT ATYYCA RDGT IAAMDY FDYWGQG TLVTVS S
DIQMTQSPSS LSA SVGD RVTITCL AS E D ISNYLAWYQ QKPGKAP KLLIYHT SRLQDGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQ QGY RFPLTF GGGT KVEI K
Abrilumab
Whole mAb
G2
Kappa
Phase-II
Discontinued
QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK
na
na
null
null
null
2,014
2015
α4β7
Amgen;AstraZeneca
na
na
Crohn's disease;Ulcerative colitis
na
null
Q VQLVQ SGA EVK KPGA SVKVSCKV SGY T LSD LSIHWVR QAPGKG LEWMG G F DPQDGE TIYAQKF QG RVTMT EDTSTDT AYMELS SLKSEDT AVYYCA TGSSSSW F DPWGQG TLVTVS S
DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWYQ QKPGKAP KLLIYG ASNLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFANYYCQ QANSFPW T FGQGT KVEI K
Acapatamab
Bispecific scFv
na;na
Kappa;Lambda
Phase-I/II
Active
QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAIISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGFPLLRHGAMDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIK
EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSS
QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL
None;None
None;None
None;None
2,020
2021
FOLH1;CD3E
Amgen
na
Cancers;Prostrate cancer;Metastatic cancer
na
BiTE Technology
null
Q VQLVES GGG LV KPGE SLRLSCA ASGF TF SD YYMYWVR QAPGKC LEWVAIIS DGG YYTYYS DI I KG RFTISR DNAKNS LYLQMN SLKAEDT AVYYC ARGFP LLR HGAMDYWGQG TLVTVS S
DI QMT QSPSS LSA SVGD RVTITCK ASQNVDTN VAWYQ QKPGQAPK SLIYSASYVYWD VPSRFSGSASGT DFTLTISS VQSEDF ATYYCQQ YDQ QLITF GCGT KLEI K
Acasunlimab
Bispecific mAb
G1;G1
Lambda;Kappa
Phase-I/II
Active
EVQLLEPGGGLVQPGGSLRLSCEASGSTFSTYAMSWVRQAPGKGLEWVSGFSGSGGFTFYADSVRGRFTISRDSSKNTLFLQMSSLRAEDTAVYYCAIPARGYNYGSFQHWGQGTLVTVSS
SYVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDNDRPSGLPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL
EVQLVESGGGLVQPGRSLRLSCTASGFSLNDYWMSWVRQAPGKGLEWVGYIDVGGSLYYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCARGGLTYGFDLWGQGTLVTVSS
DIVMTQSPSSLSASVGDRVTITCQASEDISSYLAWYQQKPGKAPKRLIYGASDLASGVPSRFSASGSGTDYTFTISSLQPEDIATYYCHYYATISGLGVAFGGGTKVEIK
None;None
None;None
None;None
2,020
2021
CD274;TNFRSF9
Genmab;BioNTech
na
Solid tumours
na
na
null
E VQLL EPGGG LV QPGG SLRLSCE ASGST FSTYAMSWVR QAPGKG LEWVS GFSGSGG FTFYA DSVRG RFTISR DSSKN TLFLQMS SLRAEDT AVYYCAI PARGYNYGS FQH WGQG TLVTVS S
SY VL TQPPS VSV APGQ TARITC GGNNIGSK SVHWYQ QKPGQAP VLVVY DDNDRPSGLPERFSGSNSGN TATLTISRVE AGDE ADYYCQVWD SSSD HVVFG GGT KLTV L
Acrixolimab
Whole mAb
G4
Kappa
Phase-I
Active
QVQLVESGGGVVQPGRSLRLSCAASGFTFLRYAMHWVRQAPGKGLEWVAVISYDGRYKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTTTTFDSWGQGTLVTVSS
DIVMTQTPLSLPVTPGEAASISCRSSQSLLDSEDGNTYLDWYLQKPGQSPQLLIYTLSHRASGVPDRFSGSGSGTDFTLEISRVEAEDVGVYYCMQRRDFPFTFGQGTKVDIK
na
na
null
null
null
2,022
na
PDCD1
Y-Biologics
na
Solid tumours
na
na
null
Q VQLVES GGG VV QPGR SLRLSC AASGF TFLRYAMHWVR QAPGKGL EWVAVIS YDGR YKYYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCTT T T FDSWGQ GTLVTVS S
DI VMT QTPLSLPVTPGEA ASISC RSSQ SLLD SEDGN TYLDWYL QKPGQSP QLLIYTLSH RASGVPDRFSGSGSGTD FTLEISRVE AEDV GVYYCMQ RRDFPF T FGQGT KVDI K
Actoxumab
Whole mAb
G1
Kappa
Phase-III
Discontinued
QVQLVESGGGVVQPGRSLRLSCAASGFSFSNYGMHWVRQAPGKGLEWVALIWYDGSNEDYTDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWGMVRGVIDVFDIWGQGTVVTVSS
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKVEIK
na
na
null
null
null
2,012
2013
Toxin A
Bristol-Myers Squibb;Merck;University of Massachussets Medical School
na
na
Clostridium difficile
Medarex HuMAb Mouse
null
Q VQLVES GGG VV QPGR SLRLSC AASGF SF SNY GMHWVRQ APGKGL EWVALIWY DGSNEDYTDS VKGRFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RWGM VRGVIDVFDI WGQG TVVTVS S
DIQ MT QSPSS VSAS VGD RVTITCR ASQGIS SWLAWY QHKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYC QQANSFPW T FGQGT KVEI K
Adalimumab
Whole mAb
G1
Kappa
Approved
Active
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK
na
na
6cr1:HL/4nyl:AB:CD:EF:HL
3wd5:HL
null
1,999
2000
TNFA
Abbvie;MedImmune;180 Life Sciences
Ankylosing spondylitis;Behcet's syndrome;Crohn's disease;Hidradenitis suppurativa;Juvenile rheumatoid arthritis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis;Rheumatoid arthritis;Spondylarthritis;Ulcerative colitis;Uveitis;Pyoderma
Dupuytren's contracture;Cognition disorders;Frozen shoulder;Non-alcoholic steatohepatitis
Interstitial cystitis
CAT Phage Display
null
E VQLVES GGG LV QPGR SLRLSC AASGFT F DDY AMHWVRQ APGKGL EWVSAITW NSGH ID YADSVE GRFTISR DNAKN SLYLQMNS LRAEDT AVYYCAKVSYL STASSLD Y WGQG TLVTVS S
DIQ MT QSPSS LSA SVGD RVTITCR ASQG IRNYLAWYQ QKPGKAP KLLIYAA STLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDVATYYCQR YNRAPY T FGQGT KVEI K
Adebrelimab
Whole mAb
G4
Kappa
Preregistration
Active
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWMGRIGPNSGFTSYNEKFKNRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGGSSYDYFDYWGQGTTVTVSS
DIVLTQSPASLAVSPGQRATITCRASESVSIHGTHLMHWYQQKPGQPPKLLIYAASNLESGVPARFSGSGSGTDFTLTINPVEAEDTANYYCQQSFEDPLTFGQGTKLEIK
na
na
null
null
null
2,019
2020
PDL1
Jiangsu Hengrui Medicine;Atridia
na
Small cell lung cancer;Non-small cell lung cancer;Oesophageal cancer;Cancer;Solid tumours
Haematological malignancies
na
null
Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYWMHWVR QAPGQG LEWMGRI GPNSGFTSYNEKFKN RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RGGSSYD YFD YWGQG TTVTVS S
D IVLTQ SPA SLAV SPGQ RATITCR ASE SVSIH G THLMHWYQ QKPGQPP KLLIYAA SNLESGVP ARFS GSGSGT DFTLTIN PVEAEDTA NYYCQQ SFEDPL T FGQGT KLEI K
Adecatumumab
Whole mAb
G1
Kappa
Phase-II
Discontinued
EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDMGWGSGWRPYYYYGMDVWGQGTTVTVSS
ELQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQPEDSATYYCQQSYDIPYTFGQGTKLEIK
na
na
null
null
null
2,004
2004
EPCAM
Micromet Inc;Merck Sorono;Amgen
na
na
Breast cancer;Colorectal cancer;Prostate cancer
na
Sequence sourced through https://www.tandfonline.com/doi/full/10.1080/19420862.2022.2123299
E VQLLES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAVISY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KDMGWGSGWRP YYYYGMDV WGQG TTVTVS S
ELQ MT QSPSS LSA SVGD RVTITCR TSQS ISSYLNWY QQKPGQPP KLLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQPEDSA TYYCQQS YDIPY T FGQGT KLEI K
Adintrevimab
Whole mAb
G1
Lambda
Phase-II/III
Active
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSSISEDGYSTYYPDSLKGRFTISRDSAKNSLYLQMNSLRADDTAVYYCARDFSGHTAWAGTGFEYWGQGTLVTVSS
QSVLTQPPSVSGAPGQRITISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYGSSSRNSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSVLYTFGTGTKVTVL
na
na
null
null
null
2,021
2022
SARS-CoV-2 Spike
Adagio Therapeutics
na
COVID-19
na
na
null
E VQLVES GGG LV KPGG SLRLSC AASGF TFSSYYMNWVR QAPGKGL EWVSSI SEDGY STY YPDSLKG RFTISR DSAKN SLYLQMNSL RADDT AVYYCAR DFSGHT AW AGTG FEYW GQG TLVTVS S
QSVLTQPPSVSGAPGQ RITISCT GSSSNIGAG YDVHWYQ QLPGTAP KLLIYG SSSRNSGVPDRFSGSKSGTS AS LAI TGLQAEDEAD YYCQS YDSSL SVLYTF GTGT KVTV L
Aducanumab
Whole mAb
G1
Kappa
Approved
NFD
QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLYLQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK
na
na
6cnr:HL/6co3:HL
null
null
2,013
2014
APP
Biogen;Neurimmune
Alzheimer's disease
na
na
na
null
Q VQLVES GGG VV QPGR SLRLSC AASGF AFS SY GMHWVRQ APGKGL EWVAVIWF DGT KKYYTD SVKG RFTISR DNSKN TLYLQMNTL RAEDT AVYYCAR DRGIGARRGP YYMDVW GKG TTVTVS S
DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QSYSTP LTF GGG TKVEI K
Afasevikumab
Whole mAb
G1
Kappa
Phase-I
Discontinued
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSSGGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGLWGRGTLVTVSS
EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIK
na
na
6ppg:HL:BA
null
null
2,015
2016
IL17A
NovImmune;Genentech
na
na
Autoimmune disorders;Inflammation
na
null
E VQLVES GGG LV QPGR SLRLSC AASGFT F DDY AMHWVR QAPGKGL EWVS G IN WSSGGI GY ADSVKG RFTISR DNAKNS LYLQMN SLRAEDT ALYYCAR DIGGFG EFYWNF G L WGRG TLVTVS S
E IVLTQ SPA TLSL SPGE RATLSCR ASQS VRSY LA W Y QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPED FAVYYCQ QRSNWPPATFGGG TKVEI K
Alacizumab
di-Fab
na
Kappa
Phase-II
Discontinued
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLEWVATITSGGSYTYYVDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCVRIGEDALDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQDIAGSLNWLQQKPGKAIKRLIYATSSLDSGVPKRFSGSRSGSDYTLTISSLQPEDFATYYCLQYGSFPPTFGQGTKVEIK
na
na
null
null
null
2,007
2008
KDR
UCB
na
na
Non-small cell lung cancer
na
null
E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YG MSWVRQ APGKG LEWVATIT SGGS YTYYVD SVKG RFTISR DNAKN TLYLQMN SLRAEDT AVYYCVRI GEDAL DYW GQ GTLVTVS S
DIQ MT QSPSS LSA SVGD RVTITCR ASQD IAGSLNWLQ QKPGKA IKRLIYAT SSLDSGVPK R FSGSRSGSD YTLTISS LQPED F ATYYCLQ YGSFPPTFGQGT KVEI K
Alemtuzumab
Whole mAb
G1
Kappa
Approved
Active
QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS
DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK
na
na
1bey:HL/1ce1:HL
null
null
2,000
2001
CD52
Bayer HealthCare Pharmaceuticals Inc.;Dana-Farber Cancer Institute;German CLL Study Group;Ohio State University Comprehensive Cancer Center;Sanofi;Sanofi Oncology;University of Cologne;University of Cambridge
Chronic lymphocytic leukaemia;Multiple sclerosis
Lymphoma;T-cell prolymphocytic leukaemia
Rheumatoid arthritis;Diffuse large B cell lymphoma;Graft-versus-host disease;Sezary syndrome;T-cell lymphoma
na
null
Q VQLQE SGPGL V RPSQ TLSLTCTV SG FTFTDFYMNWVR QPPGRGL EWIGFIR DKAKGY TTEY NPSVKG RVTMLVD TSKN QFSLRLSS VTAAD TAVYYCA REGHTAAPFDYWGQG SLVTVS S
DIQ M TQSPSS LSA SVGD RVTITCK ASQN IDKYLNWYQ QKPGKAP KLLIYN TNNLQTGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYYCLQH ISRPRTFGQGT KVEI K
Alirocumab
Whole mAb
G1
Kappa
Approved
Active
EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS
DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK
na
na
null
null
null
2,012
2013
PCSK9
Regeneron Pharmaceuticals;Sanofi;University Hospital Inselspital
Hypercholesterolaemia;Hyperlipoproteinaemia type IIa;Atherosclerosis;Dyslipidaemias
Coronary artery disease
na
VelocImmune Mouse
null
E VQLVES GGG LV QPGG SLRLSC AASGF TF NNY AMNWVR QAPGKGLD WVSTIS GSGGTTNYADSVKG RFIISR DSSKH TLYLQMN SLRAED TAVYYCA KDSNWGN FDL WGRG TLVTV SS
D IVMT QSPDS LAVS LGE RATINC KSSQ SVLYR SNNRN FLGWYQ QKPGQPPN LLIYWAS TRESGVPDRFSGSGSGTD FTLTISS LQAED VAVYYCQQ YYTTPY T FGQGT KLEI K
Alomfilimab
Whole mAb
G1
Kappa
Phase-II
Active
EVQLVESGGGVVRPGGSLRLSCVASGVTFDDYGMSWVRQAPGKGLEWVSGINWNGGDTDYSDSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDFYGSGSYYHVPFDYWGQGILVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVSRSYLAWYQQKRGQAPRLLIYGASSRATGIPDRFSGDGSGTDFTLSISRLEPEDFAVYYCHQYDMSPFTFGPGTKVDIK
na
na
7joo:HL
null
null
2,020
2021
ICOS
Kymab
na
Gastic cancers;Non-small cell lung cancer;Melanoma;Hepatocellular carcinoma;Esophageal cancer;Head and neck squamous cell carcinoma
na
na
null
E VQLVES GG GVV RPGG SLRLSCVA SGV TF DDYGM SWVRQ APGKGL EWVSGIN WNGGDTDYSDSVK GRFTISR DNAKN SLYLQMN SLRAEDT ALYYCAR DFYGSGS YYHV PFDYWGQ GILVTV SS
E IVLTQ SPG TLSL SPGE RATLSCR ASQS VSRSYLAWYQQK RGQAP RLLIYG ASSRATGIPDRFSGDGSGT DFTLSIS RLE PEDF AVYYC H QYDMSPFTFGPGT KVD IK
Alnuctamab
Bispecific mAb with Domain Crossover
G1;G1
Kappa;Lambda
Phase-I
Active
EVQLLESGGGLVQPGGSLRLSCAASGFTFSDNAMGWVRQAPGKGLEWVSAISGPGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKVLGWFDYWGQGTLVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVSDEYLSWYQQKPGQAPRLLIHSASTRATGIPDRFSGSGSGTDFTLAISRLEPEDFAVYYCQQYGYPPDFTFGQGTKVEIK
EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIRSKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS
QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNYANWVQEKPGQAFRGLIGGTNKRAPGTPARFSGSLLGGKAALTLSGAQPEDEAEYYCALWYSNLWVFGGGTKLTVL
None;None
None;None
None;None
2,020
2021
TNFRSF17;CD3E
Celgene Corporation
na
Multiple myeloma
na
na
null
E VQLLES GGG LV QPGG SLRLSC AASGF TF SDNAM GWVRQ APGKGL EWVSAI SGPGSS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAKVL G WF DYWGQG TLVTV SS
E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS DEYLSWYQ QKPGQAP RLLIHS ASTRATGIPDRFSGSGSGTD FTLAIS RLE PEDFAVYYCQQY GYPPDF T FGQGT KVEI K
Alsevalimab
Whole mAb
G1
Kappa
Phase-I
Active
QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSS
EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK
na
na
null
null
null
2,019
2020
VTCN1
Five Prime Therapeutics
na
Solid tumours
na
na
null
QL QLQE SGPGL V KPSE TLSLTCTV SGGSIKSGS YYWGWIR QPPGKGL EWIGNIYYS GS TY YNPSLR SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA REGSYPNQFDPWGQG TLVTVS S
E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSN LAWYQ QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYC QQYHSFP FTF GGGT KVEI K
Amatuximab
Whole mAb
G1
Kappa
Phase-II
Active
QVQLQQSGPELEKPGASVKISCKASGYSFTGYTMNWVKQSHGKSLEWIGLITPYNGASSYNQKFRGKATLTVDKSSSTAYMDLLSLTSEDSAVYFCARGGYDGRGFDYWGSGTPVTVSS
DIELTQSPAIMSASPGEKVTMTCSASSSVSYMHWYQQKSGTSPKRWIYDTSKLASGVPGRFSGSGSGNSYSLTISSVEAEDDATYYCQQWSKHPLTFGSGTKVEIK
na
na
null
4f33:BA:DC:FE:HG/4f3f:BA
null
2,010
2011
MSLN
Eisai Co Ltd;Morphotek;National Cancer Institute (USA)
na
Mesothelioma
Pancreatic cancer;Solid tumours
na
null
QV QLQ QSGPELEKPGA SVKISCK ASGY SFTGYTMNWVK QSHGKS LEWIGLIT PYNGASSYNQKFRG KATLTVD KSSST AYMDLLS LTSEDS AVYFCA RGGYDGRGF DY WGSGTP VTV SS
DI ELT QSP AIMS ASPGE KVTMTCS ASSS VSYMHWYQ QKSGTSPK RWIYD TSKLASGVPG RFS GSGSGN SYSLTISSVE AEDDA TYYCQQW SKHPL TF GSGT KVEI K
Amivantamab
Bispecific mAb
G1;G1
Kappa;Kappa
Approved
Active
QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVIWDDGSYKYYGDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGITMVRGVMKDYFDYWGQGTLVTVSS
AIQLTQSPSSLSASVGDRVTITCRASQDISSALVWYQQKPGKAPKLLIYDASSLESGVPSRFSGSESGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK
QVQLVQSGAEVKKPGASVKVSCETSGYTFTSYGISWVRQAPGHGLEWMGWISAYNGYTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDLRGTNYFDYWGQGTLVTVSS
DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWFQHKPGKAPKLLIYAASSLLSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPITFGQGTRLEIK
None;6wvz:HL
None;None
None;None
2,019
2020
EGFR;MET
Genmab;Janssen Research & Development
Non-small cell lung cancer
Gastic cancer;Oesophageal cancer;Solid tumours
na
na
null
Q VQLVES GGG VV QPGR SLRLSC AASGF TFSTYGMHWVRQ APGKG LEWVAVIW DDGS YKYY GDS VKGRFTISR DNSKN TLYLQMN SLRAED TAVYYCA RDG ITMVRGVM KDYFDYWGQG TLVTVS S
AI QLT QSPSS LSAS VGD RVTITCR ASQDIS SALVWYQ QKPGKAP KLLIYD ASSLESGVPSRFSGSESGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LTF GGG TKVEI K
Amlitelimab
Whole mAb
G4
Kappa
Phase-II
Active
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWVSTISGSGGATRYADSVKGRFTISRDNSRNTVYLQMNSLRVEDTAVFYCTKDRLIMATVRGPYYYGMDVWGQGTTVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPNLLIYAASSLQSGVPSRFSGSGSETDFTLTISSLQPEDFATYYCQQSHSVSFTFGPGTKVDIK
na
na
null
null
null
2,020
2021
TNFSF4
Kymab
na
Atopic dermatitis
na
na
null
E VQLVES GGG LV QPGG SLRLSC AASGF TFS NY AMNWVR QAPGKG LEWVSTIS GSGGA TRY ADSVKG RFTISR DNSRN TVYLQMN S LRV ED TAVFYC TKDR LIMATVR GPY YYGMDV WGQG TTVTVS S
DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLNWYQ QKPGKAPN LLIYAA SSLQSGVPSRFSGSGSET DFTLTIS SLQPE DFA TYYC QQSH SVSFTF GPGT KVDI K
Amubarvimab
Whole mAb
G1
Kappa
Phase-II/III
Active
EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMNWVRQAPGKGLEWVSLIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYHCARDLVVYGMDVWGQGTTVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPTFGQGTKLEIK
na
na
7cdi:HL
7e8m:HL
null
2,021
2022
SARS-CoV-2 Spike RBD
Brii Biosciences
na
COVID-19
na
na
null
E VQLVES GGG LV QPGG SLRLSC AASG ITVS SNY MNWVR QAPGKGL EWVSLIY SGGS TYYA DSVKG RFTISR DNSKN TLYLQMNS LRAEDT AVYHC ARD LVVYGMDV WGQG TTVTVS S
E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QYGSSPTFGQGT KLEI K
Anbenitamab
Bispecific mAb
G1;G1
Kappa;Kappa
Phase-II/III
Active
EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK
None;1fvc:DC:BA/1n8z:BA/4hkz:BA/4ub0:HL/5xhg:BA:DC/5xhf:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/6mh2:AB:CD/6oge:ED/7mn8:DC
None;1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC
None;5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL
2,020
2021
ERBB2 (Domain II);ERBB2 (Domain IV)
Alphamab
na
Breast cancer;Gastric cancer
na
na
4llu is 94.7% identical to ERBB2 (domain II) Fv
E VQLVES GGG LV QPGG SLRLSC AASGF TFT DY TMDWVR QAPGKG LEWVADV NPNSGGS IY NQRFKG RFTLSVD RSKN TLYLQMNS LRAEDT AVYYCA RNLGPS FYFDY WGQG TLVTVS S
DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K
Andecaliximab
Whole mAb
G4
Kappa
Phase-III
Discontinued
QVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVIWTGGTTNYNSALMSRFTISKDDSKNTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYTFGGGTKVEIK
na
na
5th9:HL:IM:JN
null
null
2,016
2017
MMP9
Gilead Sciences
na
na
Chronic obstructive pulmonary disease;Crohn's disease;Cystic fibrosis;Rheumatoid arthritis;Ulcerative colitis;Gastric cancer;Solid tumours;Glioblastoma
na
null
QV QLQE SGPGL V KPSE TLSLTCTV SGF SLLSYGVHWVR QPPGKGL EWLGVIWT GGTTNYNSA LMSRFTIS KDDSKN TVYLKM NSLKTEDT AIYYCARYY YGMDYWGQG TLVTVS S
DIQ MT QSPSS LSA SVGD RVTITCK ASQD VRNT VAWYQ QKPGKAP KLLIYS SSYRNTGVPDRFSGSGSGTD FTLTISS LQAED VAVYYC Q QHYITP YT FGGGT KVEI K
Anetumab
Whole mAb ADC
G1
Lambda
Phase-II
Active
QVELVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQAPGKGLEWMGIIDPGDSRTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARGQLYGGTYMDGWGQGTLVTVSS
DIALTQPASVSGSPGQSITISCTGTSSDIGGYNSVSWYQQHPGKAPKLMIYGVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDIESATPVFGGGTKLTVL
na
na
null
null
null
2,013
2014
MSLN
Bayer HealthCare;ImmunoGen;MorphoSys;National Cancer Institute (USA)
na
Lung cancer;Mesothelioma;Ovarian cancer;Pancreatic cancer;Solid tumours;Non-small cell lung cancer;Malignant thymoma
Fallopian tube cancer;Peritoneal cancer
MorphoSys HuCAL Phage Display
null
Q VELVQ SGA EVK KPGE SLKISC KGSGY SFTSYWIGWVR QAPGKG LEWMGII DPGDSRT RY SPSFQG QVTIS ADKS ISTAYLQWS SLKASDT AMYYC ARGQ LY GG TY MDGWGQG TLVTVS S
DI ALT QPA SV SGSPGQ SITISCT GTSSDIGGY NSVSWYQ QHPGKAP KLMIYGV NNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYCSSY DIESATP V FGGGT KLTV L
Anifrolumab
Whole mAb
G1
Kappa
Approved
Active
EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK
na
na
4qxg:HL
null
null
2,013
2014
IFNAR1
Medarex;Medical University of Vienna;MedImmune
Systemic lupus erythematosus
Lupus nephritis
Rheumatoid arthritis;Scleroderma
Medarex UltiMAb Mouse
null
E VQLVQ SGA EVK KPGE SLKISC KGSG YIFT N YWIAWVR QMPGKGLE SMGII YPGDSD IRY SPSFQG QVTIS ADKS ITTAYLQWS SLKASDT AMYYCAR HDIEGFDYWGRG TLVTVS S
E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSSS FFAWYQ QKPGQAP RLLIYG ASSRATGIPDRLSGSGSGT DFTLTITR LEPED FAVYYCQ QYDSSA ITF GQGT RLEI K
Anivovetmab
Canine Whole mAb
G2
Kappa
Unknown
Active
QVQLKESGPGLVAPSQTLSLTCTVSGFSLSSYHVHWVRQPPGKGLEWLGVMWNDGDTSYNLALNSRLSISRDTSKSQVFFKMSSLQTEDTATYYCARPELPGLTYGVWFPYWGQGTLVTVSA
DIVMTQTPASMSISVGDRVTMNCKASQNVDSNVDWYQQKTGQSPNLLIYKASNRNTGVPDRFTGSGSGTDFTFTISNMQAEDLAVYYCMQSTSYPLTFGSGTKLEIK
na
na
null
null
3iy6:BA/3jcx:HL
2,022
na
VP2 (Canine)
TBC
TBC
TBC
TBC
TBC
null
Q VQLKE SGPGL V APSQ TLSLTCTV SGF S LS SYHVHWVR QPPGKGL EWLGVMW NDGDTS YNLAL NS RLSIS RDTSKS QVFFKM SSLQTEDT ATYYCA RPELPGL TYGVWF PYWGQG TLVTVS A
D IVMT QTPA SMSIS VGD RVTMNCK ASQNVDSNV DWYQQ KTGQSPN LLIYKA SNRNTGVPDRFTGSGSGT DFTFTIS NMQAED LAVYYCM QSTSYP LTF GSGT KLEI K
Anrukinzumab
Whole mAb
G1
Kappa
Phase-II
Discontinued
EVQLVESGGGLVQPGGSLRLSCAASGFTFISYAMSWVRQAPGKGLEWVASISSGGNTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARLDGYYFGFAYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCKASESVDNYGKSLMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGGGTKVEIK
na
na
null
null
null
2,007
2008
IL13
Pfizer;Wyeth
na
na
Asthma;Ulcerative colitis
na
null
E VQLVES GGG LV QPGG SLRLSC AASGF TFISYAMSWVR QAPGKG LEWVASIS SGGNT Y YPDSVK GRFTIS RDNAKN SLYLQMNS LRAEDT AVYYCARL DG YYFGFAYW GQG TLVTVS S
DIQ MT QSPSS LSA SVGD RVTITCK ASESVD NYGKSLMHWYQ QKPGKAP KLLIYRA SNLESGVPSRFSGSGSGTD FTLTIS SLQP EDFA TYYCQ QSNEDPWTFGGG TKVEI K
Anselamimab
Whole mAb
G1
Kappa
Phase-III
Active
QVQLKESGPGLVAPSQSLSITCTVSGFSLSSYGVSWVRQPPGKGLEWLGVIWGDGSTNYHPNLMSRLSISKDISKSQVLFKLNSLQTDDTATYYCVTLDYWGQGTSVTVSS
DVVMTQTPLSLPVSLGDQASISCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGLYFCFQTTYVPNTFGGGTKLEIK
na
na
null
null
null
2,021
2022
Light Chain Amyloid Fibrils
Caelum Biosciences
na
AA amyloidosis
na
na
Oct '22: Amended target. Targets a conserved epitope across light chain amyloid fibrils: Am J Pathol. 2000;157(4):1239–46;Clin Cancer Res. 2003;9(10):3831S-3838S;Biochemistry. 2007;46(5):1240–7.
Q VQLKE SGPGL V APSQ SLSITCTV SG FSL S SYGVSWVR QPPGKGL EWLGVIW GDGSTNYHPNLMS RLSI SKDISKS QVLFKLNS LQTDDTA TYYCVTLD YWGQG TSVTVS S
DV VMT QTPLSLPVSLGDQ ASISC RSSQ SLVHR NGN TYLHWYLQ KPGQSP KLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDL GLYFCFQTTY VPNTFGGG TKLEI K
Ansuvimab
Whole mAb
G1
Kappa
Approved
Active
EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTTYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSS
DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIK
na
na
null
5fha:HL/5fhc:HL
null
2,020
2021
Zaire Ebolavirus GP1
Ridgeback Biotherapeutics
Zaire ebolavirus infection
na
na
na
null
E VQLVES GGG LI QPGG SLRLSC AASGF ALRMY DM HW V R QT IDKR LEWVSAV GPSGDTT YA DSVKG RFAVS R ENAKNS LSLQM N S LTAGDT AIYYCVR SDRGV AGLF DSWGQ GILVTVS S
DIQ MT QSPSS LSA SVGD RITITCR AS Q A FDNYVAWYQ QRPGKVP KLLISA A SA LHAGVPS R FSGSGSGT HFTLTIS SLQP EDVAT YYC QNYNSAP LTF GGG TKVEI K
Anumigilimab
Whole mAb
G4
Kappa
Phase-I
Active
EVQLLESGGGLVQPGGSLRLSCAASGFTFSLYWMGWVRQAPGKGLEWVSSISSSGGVTPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKLGELGWFDPWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQGISSYLNWYQQKPGKAPKLLIYYASNLQNGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIK
na
na
null
null
null
2,021
2022
CSF3R
CSL Behring
na
Inflammatory diseases;Hidradenitis suppurativa;Localised pustular psoriasis
na
na
null
E VQLLES GGG LV QPGG SLRLSCA ASGF TFSLYWMGWVR QAPGKG LEWVSSIS SSGGVTPYADSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAK LGELGW F DPWGQG TLVTVS S
DIQ MT QSPSS LSA SVGD RVTITCR ASQGI SSYLNWY QQKPGKAP KLLIYYA SNLQNGVPS RF SGSGSGTD FTLTIS SLQPE DFA TYYCQ QSYSTP LTF GGG TKVEI K
Anvatabart
Whole mAb ADC
G1
Kappa
TBC
Active
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK
na
na
1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD/6oge:ED/7mn8:DC
1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC
5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6mxr:AB:HL
2,022
na
ERBB2
TBC
TBC
TBC
TBC
Humanised
Anvatabart has an identical V domain to Coprelotamab, Cinrebafusp, Timigutuzumab, and Trastuzumab
E VQLVES GGG LV QPGG SLRLSCA ASGFNIKD TYIHWVRQ APGKG LEWVARIY PTNGY TRYA DSVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCS RWGGDG FYAMD YWGQG TLVTVS S
DIQ MT QSPSS LSA SVGD RVTITCR ASQD VNTA VAWYQ QKPGKAP KLLIYSASFLY SGVPSRFSGSRSGTD FTLTIS SLQP EDFAT YYCQ QHYTTPPTFGQGT KVEI K
Anzurstobart
Whole mAb
G1
Kappa
Phase-I
Active
QVQLVQSGAEVKKPGASVKVSCKASGYTFRGYGISWVRQAPGQGLEWMGWISAYGGETNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAREAGSSWYDFDLWGRGTLVTVSS
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGASFPITFGGGTKVEIK
na
na
null
null
null
2,022
na
SIRPα
Celgene Corporation
na
Acute myeloid leukaemia;Myelodysplastic syndromes
Non-Hodgkin's lymphoma;Solid tumours
na
null
Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFRGYGISWVRQ APGQGL EWMGWISA YGGETNY AQKL QG RVTMTT DTSTS TAYMELRSL RSDDT AVYYCAR EAGSS WYDFDL WGRG TLVTV SS
DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWY QQKPGKAP KLLIYAA SNLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYC QQGASF PITF GGG TKVEI K
Apamistamab
Whole mAb Radiolabelled
G1
Kappa
Phase-III
Active
EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPTSSTINFTPSLKDKVFISRDNAKNTLYLQMSKVRSEDTALYYCARGNYYRYGDAMDYWGQGTSVTVSS
DIALTQSPASLAVSLGQRATISCRASKSVSTSGYSYLHWYQQKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPFTFGSGTKLEIK
na
na
null
null
null
2,018
2019
PTPRC
Actinium Pharmaceuticals;Fred Hutchinson Cancer Research Center
na
Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma
Hodgkin's disease;Non-Hodgkin's lymphoma
na
null
E VKLLES GGG LV QPGG SLKLSCA ASGFDFSR YWMSWVR QAPGKGL EWIGEI NPTSS TINF TPSLKD KVFISR DNAKN TLYLQMSKV RSEDT ALYYC ARGN YYRY GDAMDYWGQG TSVTVS S
DI ALT QSPA SLAVS LGQ RATISCRA SKSVSTSGY SYLHWYQ QKPGQPP KLLIYLA SNLESGVP ARFS GSGSGTD FTLNIHP VEEEDA A TYYC QHSRELP FT FGSGT KLEI K
Apitegromab
Whole mAb
G4
Lambda
Phase-III
Active
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLLVRFLEWSHYYGMDVWGQGTTVTVSS
QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNTVHWYQQLPGTAPKLLIYSDNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGVFGGGTKLTVL
na
na
null
null
6umx:HL:hl
2,020
2021
pro-GDF-8
Scholar Rock
na
Spinal muscular atrophy;Muscular atrophy;Spinal cord injuries
na
na
null
Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKG LEWVAVISY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYC ARDLLVRFLEWSHY YGMD V WGQG TTVTVS S
QSVLTQPPSASGTPGQ RVTISC SGSSSNIGSN TVHWYQQ LPGTAP KLLIY SDNQRPSGVPDRFSGSKSGTS ASL A I SGLQSEDEAD YYCAAW DDSLNGVFGGGT KLTV L
Aprutumab
Whole mAb ADC
G1
Lambda
Phase-I
Discontinued
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGTSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVRYNWNHGDWFDPWGQGTLVTVSS
QSVLTQPPSASGTPGQRVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYENYNRPAGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSLNYWVFGGGTKLTVL
na
na
null
null
null
2,016
2017
FGFR2
Bayer
na
na
Solid tumours
na
null
E VQLLES GGG LV QPGG SLRLSC AASGF TFSSYAMSWVR QAPGKGL EWVSAI SGSGT STYYA DSVKG RFTISR DNSKN TLYLQMNS LRAEDT AVYYCARVRYN WNHGDWFDPWGQ GTLVTVS S
QSVLTQPPSASGTPGQ RVTISC SGSSSNIGNN YVSWYQQ LPGTAP KLLIYE NYNRPAGVPDRFSGSKSGT SASLAI SGLRSEDEAD YYC SSWDDSLN YWVF GGGT KLTV L
Arcitumomab
Whole mAb
G1
Kappa
Approved (w)
NFD
EVKLVESGGGLVQPGGSLRLSCATSGFTFTDYYMNWVRQPPGKALEWLGFIGNKANGYTTEYSASVKGRFTISRDKSQSILYLQMNTLRAEDSATYYCTRDRGLRFYFDYWGQGTTLTVSS
QTVLSQSPAILSASPGEKVTMTCRASSSVTYIHWYQQKPGSSPKSWIYATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQHWSSKPPTFGGGTKLEIK
na
na
1clo:HL
null
null
1,995
1996
CEA
Immunomedics;Giliad Sciences
Colorectal cancer
na
na
na
null
E VKLVES GGG LV QPGG SLRLSC ATSGF TFTDYYMNWVR QPPGKA LEWLGFIG NKANGY TTEYSASVKGRFTIS RDKSQ SILYLQMNTL RAEDS ATYYCT RDRG LRFYFDY WGQG TTLTVS S
QT VL SQSP AILS ASPGE KVTMTCR ASSS VTYIHWYQ QKPGSSPK SWIYAT SNLASGVP ARFS GSGSGT SYSLTISRVE AEDA ATYYCQH WSSKPPTFGGGT KLEI K
Ascrinvacumab
Whole mAb
G2
Kappa
Phase-II
Discontinued
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGEYYWNWIRQHPGKGLEWIGYIYYSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARESVAGFDYWGQGTLVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGTSSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTRLEIK
na
na
null
null
null
2,015
2016
ACVRL1
Duke University Medical Center;Fondazione IRCCS Istituto Nazionale dei Tumori;Pfizer;Suzhou Kintor Pharmaceuticals
na
na
Colorectal cancer;Liver cancer;Solid tumours;Urogenital cancer;Age-related macular degeneration;Cancer;Liver Cancer
na
null
QV QLQE SGPGLVKPSQ TLSLTCTV SGGSISSG EYY WNWIR QHPGKGL EWIGYIYYS GST Y YNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYCA RESVAG FDY WGQG TLVTV SS
E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSY LAWYQ QKPGQAP RLLIYG TSSRATGIPDRFSGSGSGT DFTLTISR LE PEDFA VYY CQQ YGSSP ITF GQGT RLEI K
Aselizumab
Whole mAb
G4
Kappa
Phase-II
Discontinued
EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVASISTGGSTYYPDSVKGRFTISRDNAKNTLYLQMNSLRAEDTAVYYCARDYDGYFDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCKASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASNLESGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPWTFGQGTKVEIK
na
na
null
null
null
2,003
2003
L-Selectin
PDL Biopharma
na
na
Adult respiratory distress syndrome;Crohn's disease;Psoriasis;Reperfusion injury;Shock
na
null
E VQLVES GGG LV QPGG SLRLSC AASGF TFSTYAMSWVR QAPGKG LEWVASIS TGGST Y YPDSVK GRFTISR DNAKN TLYLQMNS LRAEDT AVYYCAR DYDGY FDY WGQG TLVTV SS
DI QMT QSPSS LSA SVGD RVTITCK ASQS V DYDGD SYMNWYQ QKPGKAP KLLIYAA SNLESGIPSRFSGSGSGTD FTLTISS LQPED F ATYYCQ QSNEDPWTFGQGT KVEI K
Astegolimab
Whole mAb
G2
Kappa
Phase-II
Active
EVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWIGWVRQMPGKGLEWMGIIYPGNSDTRFSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHGTSSDYYGLDVWGQGTTVTVSS
DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQDDNFPLTFGGGTKVEIK
na
na
null
null
null
2,019
2020
IL1RL1
Amgen;Genentech;University of Leicester
na
Allergic asthma;Atopic dermatitis;Chronic obstructive pulmonary disease
Asthma;Rhinosinusitis
na
null
E VQLVQ SGA EVK KPGE SLKISC KGSGYS F T NYWIGWVRQ MPGKGL EWMGIIY PGNSDTRFSPSFQG QVTIS ADKS ITTAYLQWS SLKASDT AMYYCA RHGTSSDY YGLDVW GQG TTVTVS S
DIQMTQSPSS LSA SVGD RVTITCQ ASQD ISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATY YC QQDDNFP LTF GGG TKVEI K
Atezolizumab
Whole mAb
G1
Kappa
Approved
Active
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK
na
na
5x8l:FK:HM:GL:JO:SN
5xxy:HL
null
2,014
2015
CD274
Amgen;ARCAGY/GINECO Group;BioLineRx;Chugai Pharmaceutical;Clovis Oncology;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;Exelixis;Fondazione Michelangelo;GEICO (Spanish Ovarian Cancer Research Group);Genentech;GERCOR;Gradalis;H. Lee Moffitt Cancer Center and Research Institute;Immune Design;Incyte Corporation;Johns Hopkins University;Kaiser Permanente;M. D. Anderson Cancer Center;Memorial Sloan-Kettering Cancer Center;National Cancer Center (Korea);National Cancer Institute (USA);Netherlands Cancer Institute;Roche;Sanofi;Seattle Genetics;University Hospital Southampton NHS Foundation Trust;University Medical Center Groningen;University of California;University of California at San Francisco;University of Oklahoma;Yale University
Non-small cell lung cancer;Urogenital cancer;Breast cancer;Small cell lung cancer
Bladder cancer;Cervical cancer;Colorectal cancer;Fallopian tube cancer;Head and neck cancer;Liver cancer;Malignant melanoma;Ovarian cancer;Peritoneal cancer;Prostate cancer;Renal cell carcinoma;Anal cancer;Brain metastases;Chronic lymphocytic leukaemia;Cutaneous T-cell lymphoma;Diffuse large B cell lymphoma;Endometrial cancer;Gastric cancer;Gynaecological cancer;Mantle-cell lymphoma;Marginal zone B-cell lymphoma;Oesophageal cancer;Soft tissue sarcoma;Solid tumours;Thyroid cancer;Waldenstrom's macroglobulinaemia;Acute myeloid leukaemia;Follicular lymphoma;Glioblastoma;Pancreatic cancer;Haematological malignancies;Multiple myeloma;Non-Hodgkin's lymphoma
Hodgkin's disease;Myelodysplastic syndromes
Human Phage Display
null
E VQLVES GGG LV QPGG SLRLSC AASGF TF SDS WIHWVRQ APGKG LEWVAWI SPYGGS TYYAD SVKG RFTISA DTSKN TAYLQMN SLRAEDT AVYYCAR RHWPGGFD Y WGQG TLVTVS S
DIQ MT QSPSS LSA SVGD RVTITCR ASQD VSTA VAWY Q QKPGKAP KLLIYSASFLY SGVPSRFSGSGSGTD FTLTIS SLQ PEDFAT YYCQQYLY HPATFGQGT KVEI K
Atibuclimab
Whole mAb
G4
Kappa
Phase-II
Active
DVQLQQSGPGLVKPSQSLSLTCTVTGYSITSDSAWNWIRQFPGNRLEWMGYISYSGSTSYNPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCVRGLRFAYWGQGTLVTVSS
DIVLTQSPASLAVSLGQRATISCRASESVDSYVNSFLHWYQQKPGQPPKLLIYRASNLQSGIPARFSGSGSRTDFTLTINPVEADDVATYYCQQSNEDPYTFGGGTKLEIK
na
na
null
null
null
2,020
2021
CD14
ICOS Corporation;Implicit Bioscience
na
Acute lung injury;COVID-19
Adult respiratory distress syndrome;Motor neuron disease;Septic shock
na
null
DV QLQQ SGPGLVKPSQ SLSLTCTVT G YSI TSDS AWNWIR QFPGNR LEWMGYISY SGSTSYNPSLK SRISITR DTSKN QFFLQLN S V TTEDTA TYYCVR G LRFAYW GQG TLVTVS S
D IVLT QSPA SLAVS LGQ RATISCR ASES VDSYVNSFLHWYQ QKPGQPP KLLIYRA SNLQSGIPA RF SGSGSRT DFTLTI NPVEADD V ATYYCQ QSNEDPYTFGGGT KLEI K
Atidortoxumab
Whole mAb
G1
Kappa
Phase-II
Discontinued
EVQLQESGPGLVRPSETLSLTCAVSGYSISSGMGWGWIRQPPGKGLEWIGSIDQRGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDAGHAVDMDVWGKGTTVTVSS
DIQMTQSPSSVSASVGDRVTITCRASQGISRWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYVFPLTFGGGTKVEIK
na
na
null
null
null
2,017
2018
Toxin A
Adimab;Arsanis;X4 Pharmaceuticals
na
na
Staphylococcal infections
na
null
E VQLQ ESGPG LV RPSE TLSLTCAV SGY SI SSGMG WGWIR QPPGKGL EWIGSI DQRGS TYY NPSLKS RVTISVD TSKN QFSLKLSS VTAADT AVYYCA RDAGH AVDMDV WGKG TTVTVS S
DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISRWLAWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATY YC QQGY VFPLTF GGG TKVEI K
Atinumab
Whole mAb
G4
Kappa
Phase-I
Discontinued
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMSWVRQAPGKGLEWVATIKQDGSQKNYVDSVKGRFTISRDNAKNSLYLRLNSLRAEDTAVYYCATELFDLWGRGSLVTVSS
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTKLEIK
na
na
null
null
null
2,010
2011
RTN4
Novartis
na
na
Spinal cord injuries
na
null
E VQLVES GGG LV QPGG SLRLSC AASGF TF SN YWMSWVR QAPGKG LEWVATIK QDGSQK NYVD SVKG RFTISR DNAKN SLYLRLN SLRAEDT AVYYCA TEL F DLWGRGS LVTV SS
E IVLTQ SPA TLSL SPGE RATLSCR ASQS VSSY LAWY QQKPGQAP RLLIYD ASNRATGIP ARF SGSGSGTD FTLTIS SLEPE D FAVYYCQ QRSNWP ITF GQGT KLEI K
Atisnolerbart
Whole mAb
G4
Kappa
TBC
Active
QVQLVQSGAEVKKPGASVKVSCKASGYTFISYNIFWVRQATGQGLDWMGWMNPFRNNAGYAQKFQGRVTVTWDTSISTAYMELSSLSSEDTAIYYCAREHGSSWGFFDYWGQGTLVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK
na
na
7mxl:JK/7n0v:HL
null
null
2,022
na
Bet v 1
Regeneron
TBC
TBC
TBC
na
Antigen: Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1. Also known as REGN5715. Identical V region sequence to Bremzalerbart.
Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFISYNIFWVR QATGQGLD WMGW MNPFRNNAGY AQKF QG RVTVTW DTSI STAYMELS SLSSEDT AIYYCAR EHGSSW GFFD YWGQG TLVTV SS
E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYC Q QYGSSPWTFGQGT KVEI K
Atoltivimab
Whole mAb
G1
Kappa
Phase-I
Discontinued
QVQLVESGGGVVQPGRSLRLSCAASGFTFNNYGMHWVRQAPGMGLEWVAVIWHDGSDKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARNWNLFDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRITITCRASQSISTYLHWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSTPPINFGQGTKLEIK
na
na
null
null
null
2,018
2019
Zaire Ebolavirus GP
Regeneron Pharmaceuticals
na
na
Ebola virus infections
na
null
Q VQLVES GGG VV QPGR SLRLSC AASGF TF NNY GMHWVRQ APGMG LEWVAVIWH DGSDK YYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA RNWN LF DYWGQG TLVTVS S
DIQ MT QSPSS LSA SVGD RITITCR ASQS ISTYLHWY QQKPGKAP KLLIYAA STLQSGVPS R FSGSGSGTD FTLTIS SLQP EDFA TYYCQ QSFSTPPINFGQGT KLEI K
Avdoralimab
Whole mAb
G1
Kappa
Phase-II
Active
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMHWVRQATGKGLEWVSAIDTGGGTYYADSVKGRFTISRENAKNSLYLQMNSLRAGDTAVYYCARDYYYYASGSYYKAFDIWGQGTMVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVSSRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPLTFGQGTKLEIK
na
na
null
null
null
2,019
2020
C5AR1
Novo Nordisk;Innate Pharma
na
Bullous pemphigoid;COVID-19;Urticaria;Liver cancer;Non-small cell lung cancer;Solid tumours
Rheumatoid arthritis
na
null
E VQLVES GGG LV QPGG SLRLSC AASGF TFSSYVMHWVR Q ATGKGL EWVSAID TGGG TYYA DSVKG RFTIS RE NAKNS LYLQMNS LRAGD TAVYYCA RD YYYY ASGS YYKAFDI WGQG TMVTVS S
E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SR YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LE PEDFA VYY CQQ YGSPL T FGQGT KLEI K
Avelumab
Whole mAb
G1
Lambda
Approved
Active
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS
QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL
na
na
4nki:HL/5grj:HL
null
null
2,015
2016
CD274
AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine
Merkel cell carcinoma;Urogenital cancer;Renal cell carcinoma
Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma;Bone metastases;Anal cancer;Cervical cancer;Vulvovaginal cancer;Meningioma
na
Human Phage Display
Avelumab and Bintrafusp have identical V domains
E VQLLES GGG LV QPGG SLRLSCA ASGF TFSSYIMMWVRQ APGKG LEWVSSI YPSGG ITFYAD TVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARIK LGT VTTVDY WGQG TLVTVS S
QSALTQPA SV SGSPGQ SITISCT GTSSDVGG YNYVSWYQ QHPGKAP KLMIYD VSNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYCSS YTSSST RVF GTGT KVTV L
Avizakimab
Whole mAb
G1
Kappa
Phase-I/II
Active
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYWMHWVRQAPGQGLEWMGTIDPSDQYTIYSQNFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYGFAMDYWGQGTLVTVSS
DIQLTQSPSSLSASVGDRVTITCRASQDISNFLNWYQQKPGKAVKLLIYYTSRLHSGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQQGHTLPRTFGGGTKVEIK
na
na
null
null
null
2,019
2020
IL21
MedImmune;Boston Pharmaceuticals
na
Systemic lupus erythematosus
Autoimmune disorders
na
null
Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTDYWMHWVR QAPGQG LEWMGTI DPSDQ YTIYSQ NFKG RVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RYGF AMD YWGQG TLVTVS S
DI QLT QSPSS LSA SVGD RVTITCR ASQD ISNFLNWYQ QKPGK AVKLLIYYT SRLHSGVPS R FSGSGSGTD YTLTIS SLQ PEDFATY Y C QQGHTLPRTFGGGT KVEI K
Axatilimab
Whole mAb
G4
Kappa
Phase-II
Active
EVTLKESGPALVKPTQTLTLTCTFSGFSLTTYGMGVGWIRQPPGKALEWLANIWWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIGPIKYPTAPYRYFDFWGQGTMVTVSS
DIQMTQSPSSLSASVGDRVTITCLASEDIYDNLAWYQQKPGKAPKLLIYYASSLQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQDSEYPWTFGGGTKVEIK
na
na
null
null
null
2,019
2020
CSF1R
Syndax Pharmaceuticals;AstraZeneca;UCB
na
Cholangiocarcinoma;Graft-versus-host disease;COVID-19
Solid tumours
na
null
E VTLKE SGPA LV KPTQ TLTLTCTF SGF SLTTYGMGVGWIR QPPGKA LEW LANIW WDDDKYYNPSLKN RLTIS KDTSKN QVVLTMT NMDPVDTA TYYCARI GPIKYPTAPY RYFDF WGQG TMVTVS S
DIQMTQSPSS LSA SVGD RVTITCL ASED IYDNLAWYQ QKPGKAP KLLIYYA SSLQDGVPS RF SGSGSGTD YTLTIS SLQPEDF ATYYCL QDSEYPW T FGGG TKVEI K
Azintuxizumab
Whole mAb ADC
G1
Kappa
Phase-I
Discontinued
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYYMAWVRQAPGKGLEWVASINYDGSSTYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDRGYYFDYWGQGTTVTVSS
DVVMTQTPLSLSVTPGQPASISCRSSQSLVHSNGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPPFTFGGGTKVEIK
na
na
null
null
null
2,016
2017
SLAMF7
AbbVie
na
na
Multiple myeloma
na
null
E VQLVES GGG LV QPGG SLRLSCA ASGF TF SD YYMAWVRQ APGKG LEWVASIN YDGS STYYVD SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCA RDRG YYFDY WGQG TTVTVS S
DV VMT QTP LSLSV TPGQP ASISCR SSQ SLVH SNGN TYLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AED VGVYFCS QSTHVPPF T FGGG TKVEI K
Bafisontamab
Bispecific Mixed mAb and Fab
G1;na
Kappa;Kappa
Phase-I/II
Active
QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS
DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGFSWVRQAPGQGLEWMGWISASNGNTYYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARVYADYADYWGQGTLVTVSS
DIQMTQSPSSVSASVGDRVTITCRASQGINTWLAWYQQKPGKAPKLLIYAASSLKSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK
5sx4:HL:JI/5sx5:JK:HL;None
None;None
None;None
2,021
2022
EGFR;MET
EpimAb Biotherapeutics
na
Non-small cell lung cancer;Solid tumours
na
na
Fv1 is Panitumumab
Q VQLQE SGPGL V KPSE TLSLTCTVS GGSVSSGD YYWTWIRQ SPGKGL EWIGHIYYS GNTNYNPSLK SRLTISID TSKT QFSLKLSS VTAADT AIYYCVR DRVTG AFDIW GQG TMVTVS S
DIQMTQSPSS LSA SVGD RVTITCQ AS QDISNYLNWYQ QKPGKAP KLLIYD ASNLETGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYFCQH FDHLP LAF GGGT KVEI K
Balstilimab
Whole mAb
G4
Kappa
Phase-III
Active
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASNGDHWGQGTLVTVSS
EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPRTFGQGTKVEIK
na
na
null
null
null
2,018
2019
PDCD1
Agenus;Ludwig Institute for Cancer Research
na
Cervial cancer;Solid tumours;Colorectal cancer;Haemangiosarcoma;Soft tissue sarcoma
na
na
null
Q VQLVES GGG VV QPGR SLRLSC AASGF TFSS Y GMHWVRQ APGKGL EWVAVIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCA SNGDHWGQ GTLVTVS S
E IVMT QSPA TLSV SPGE RATLSCR ASQSVSSN LAWYQ QKPGQAP RLLIYG ASTRATGIP ARFS GSGSGT EFTLTISS LQSED FAVYYCQQ YNNWPRTFGQGT KVEI K
Bamlanivimab
Whole mAb
G1
Kappa
Approved
Active
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGYYEARHYYYYYAMDVWGQGTAVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLSWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTITSLQPEDFATYYCQQSYSTPRTFGQGTKVEIK
na
na
7l3n:DE/7kmg:AB:DE
null
null
2,020
2021
SARS-CoV-2 Spike
Abcellera;Eli Lilly and Company;National Institute of Allergy and Infectious Diseases
COVID-19
na
na
Baiting from convalescent human B-cells
null
Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT F S NYAISWVR QAPGQGL EWMGRIIPILG IANYAQK FQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RG YY EAR HYYYYYAMD VWGQG TAVTVS S
DIQ MT QSPSS LSA SVGD RVTITCR ASQS ISSYLSWY QQKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTITS LQP EDFA TYYCQ QSYSTPRTFGQGT KVEI K
Bapineuzumab
Whole mAb
G1
Kappa
Phase-II
Discontinued
EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS
DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK
na
na
null
null
4ojf:HL/4hix:HL
2,005
2006
APP
JANSSEN Alzheimer Immunotherapy;Pfizer;Wyeth;Elan Corporation
na
na
Alzheimer's disease
na
Jain paper: "Conflicting literature sequences in FR3 of VH - AKNTLYLQMNSLRAEDTAV vs. AKNSLYLQMNSLRAEDTAL"
E VQLLES GGG LV QPGG SLRLSC AASGF TFS NYG MSWVRQ APGKG LEWVASIR SGGGR TYYS DNVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCVRYD HYSGSSDYWGQ GTLVTVS S
DV VMT QSPLSLPVTPGEPA SISC KSSQ SLL DSDGK TYLNWLL QKPGQSPQ RLIYLVSK LDSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCW QGTHFPRTFGQGT KVEI K
Bapotulimab
Whole mAb
G2
Kappa
Phase-I
Active
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGRLPYGDFWDSWGQGTLVTVSS
DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKLEIR
na
na
null
null
null
2,020
2021
ILDR2
Bayer
na
Solid tumours
na
na
null
Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT FSSYAISWVR QAPGQGL EWM GG IIPILGI A N YAQ KFQG RVTITA DKSTS TAYMELS SLRSEDT AVYYCA RGRLPYGDFWDSWGQG TLVTV SS
DI VMT QSPLSLPVTPGEPA SISC RSSQ SLLY SNGYN YLDWYL QKPGQSP QLLIYL GSNRASGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCMQA LQTPL TF GGGT KLEI R
Barecetamab
Whole mAb
G1
Lambda
Phase-I
Active
EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYDMSWVRQAPGKGLEWVSTIDLDSGSIYYADSVQGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDLHMGPEGPFDYWGQGTLVTVSS
QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYSDNHRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQGWDTSLSGHVFGGGTKLTVL
na
na
7d85:BC:EF
null
null
2,020
2021
ERBB3
ISU Abxis
na
Head and neck cancer
Solid tumours
Antibody Phage Display
null
E VQLLES GGG LV QPGG SLRLSC AASGF TF SDYDM SWVR QAPGKGL EWVSTID LDSG SIYYAD SVQG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KDLHMGPEGPFDYWGQG TLVTVS S
QSVLTQPPSASGTPGQ RVTISC SGSSSNIGSNS VS WYQ QLPGTAP KLLIY SDNHRPSGVPDRFSGSKSGT SASLAI SGLRSED E A DY YC QGWDTSLSG HVF GGGT KLTV L
Barzolvolimab
Whole mAb
G1
Kappa
Phase-II
Active
QVQLVQSGAEVKKPGASVKLSCKASGYTFTDYYINWVRQAPGKGLEWIARIYPGSGNTYYNEKFKGRATLTADKSTSTAYMQLSSLRSEDTAVYFCARGVYYFDYWGQGTTVTVSS
DIVMTQSPSSLSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISSLQPEDFADYFCQQYNSYPRTFGGGTKVEIK
na
na
null
null
null
2,021
2022
KIT
Celldex Therapeutics
na
Chronic idiopathic urticaria
na
na
null
Q VQLVQ SGA EVK KPGA SVKLSCK ASGY TFTDYYINWVR QAPGKG LEWIARI YPGSGNT YY NEKFKG RATLTA DKSTS TAYMQLS SLRSEDT AVYFC ARG VYYFD YWGQG TTVTVS S
D IVMT QSPSS LSA SVGD RVTITCK ASQNV RTNVAWYQ QKPGKAPK ALIYSASYRY SGVPDRFTGSGSGTD FTLTIS SLQ PEDFADYFCQQY NSYPRTFGGGT KVEI K
Basiliximab
Whole mAb
G1
Kappa
Approved
NFD
QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS
QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK
na
na
1mim:HL/3iu3:AB:CD:HL
null
null
1,996
1997
IL2RA
Cerimon Pharmaceuticals;Novartis
Renal transplant rejection;Transplant rejection
na
Ulcerative colitis;Uveitis
na
null
QV QLQ QSG TVLA RPGA SVKMSCK ASGYS FTRYWMHWIK QRPGQGL EWIGAI YPGNSDTSYNQK F EGK AKLTAVT SAST AYMEL SSLTHEDS AVYYC SRDYG YYFDF WGQG TTLTVS S
QI VS TQSP AIMS ASPGE KVTMTCS ASSSRS YMQWYQ QKPGTSPK RWIYD TSKLASGVP ARFS GSGSGT SYSLTISS MEAEDA ATYYCHQ RSS YTF GGGT KLEI K
Batoclimab
Whole mAb
G1
Lambda
Phase-III
Active
QLLLQESGPGLVKPSETLSLTCTVSGGSLSSSFSYWVWIRQPPGKGLEWIGTIYYSGNTYYNPSLKSRLTISVDTSKNHFSLKLSSVTAADTAVYYCARRAGILTGYLDSWGQGTLVTVSS
SYVLTQSPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSASNSGNTATLTISRVEAGDEADYYCQVWDSSSDHVVFGGGTKLTVL
na
na
null
null
null
2,019
2020
FCGRT
Immunovant Sciences
na
Graves' Ophtalmopathy;Myasthenia gravis;Autoimmune disorders;Neuromyelitis optica;Idiopathic thrombocytopenic purpura
na
na
null
Q LLLQE SGPGL V KPSE TLSLTCTV SGGSLSSS FSYWVWIR QPPGKGL EWIGTIYYS GNT Y YNPSLK SRLTISVD TSKN HFSLKLSS VTAADT AVYYCAR RAG ILTGYL DSWGQG TLVTVS S
S YVLT QSPS VSV APGQ TARITC GGNNIGSK SVHWYQ QKPGQAP VLVVY DDSDRPSGIPE RFSA SNSGN TATLTISRVE AGDE ADYYCQVWD SSSD HVVFG GGT KLTV L
Bavituximab
Whole mAb
G1
Kappa
Phase-III
Active
EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS
DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK
na
na
null
null
null
2,006
2007
Phosphatidylserine
Avid Bioservices;IMV;Massachusetts General Hospital;Merck Sharp & Dohme;Peregrine Pharmaceuticals;University of Arizona;University of Texas Southwestern Medical Center;University of Texas M. D. Anderson Cancer Center
na
Non-small cell lung cancer;Glioblastoma;Liver cancer;Solid tumours
Breast cancer;Malignant melanoma;Pancreatic cancer;Brain cancer;Hepatitis C;HIV infections;Rectal cancer;Viral haemorrhagic fevers;Influenza virus infections;Prostate cancer
na
null
EV QLQ QSGPELEKPGA SVKLSCK ASGY SFTGYNMNWVK QSHGK SLEWIGHI DPYYGDTSYNQK F RG KATLTVD KSSST AYMQLKS LTSEDS AVYYCV KGGYYG HWYFDVW GAGT TVTVS S
DI QMT QSPSS LS ASLGE RVSLTCR ASQDIGSS LNWLQQ GPDGT IKRLIYAT SSLDSGVPK R FSGSRSGSD YSLTISS LESEDF VDYYCLQYV SSPPTFGAGT KLEL K
Bavunalimab
Bispecific Mixed mAb and scFv
G1;na
Kappa;Kappa
Phase-I
Discontinued
EVQLVESGGGLVQPGGSLRLSCAASGFTFDDAWMSWVRQAPGKGLEWVAEISTKANNHATYYAESVKGRFTISRDDSKSSVYLQMNSLRAEDTAVYYCTRLATWDWYFDVWGQGTTVTVSS
DIVLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKPPKLLIYAASELESGIPARFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPFTFGSGTKLEIK
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVSFISYDGNYKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARGGHLGPFDLWGQGTMVTVSS
EIVLTQSPATLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK
None;None
None;None
None;None
2,020
2021
LAG3;CTLA4
Xencor
na
na
Solid tumours
na
Bavunalimab is the new name for Pavunalimab (PL125). (Jun '22) Corrected IMGT H25 S->A.
E VQLVES GGG LV QPGG SLRLSC AASGFTFDDA WMSWVR QAPGKGL EWVAEIST KANNH ATYYAES VKG RFTISR DDSKS SVYLQMN SLRAEDT AVYYCTR LATWD WYFDV WGQG TTVTVS S
D IVLT QSPSS LSA SVGD RVTITCRA SQS V DYDGD SYMNWYQ QKPGKPP KLLIYAA SELESGIP ARFS GSGSGTD FTLTISS LQPEDF ATYYCQ QSNEDPF T FGSGT KLEI K
Bebtelovimab
Whole mAb
G1
Lambda
Approved
Active
QITLKESGPTLVKPTQTLTLTCTFSGFSLSISGVGVGWLRQPPGKALEWLALIYWDDDKRYSPSLKSRLTISKDTSKNQVVLKMTNIDPVDTATYYCAHHSISTIFDHWGQGTLVTVSS
QSALTQPASVSGSPGQSITISCTATSSDVGDYNYVSWYQQHPGKAPKLMIFEVSDRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSAVFGGGTKLTVL
na
na
7mmo:AB:DE
null
null
2,022
na
SARS-CoV-2 Spike RBD
Eli Lilly;AbCellera
COVID-19
na
na
na
null
Q ITLK ESGP TLV KPTQ TLTLTCTF SG FSLSIS G VGVGWLR QPPGKA LEWLALIYW DDDKRYSPSLK SRLTIS KDTSKN QVVLKMTN IDPVDTA TYYC AHHS ISTIF DHWGQG TLVTVS S
QSALTQPA SV SGSPGQ SITISCTA TSSDVGD YNYVSWYQ QHPGKAP KLMIFEV SDRPSGISNRFSGSKSGN TASLTIS GLQAEDEAD YYCSS YTTSS AVF GGGT KLTV L
Becotatug
Whole mAb
G1
Kappa
TBC
Active
QVQLQESGPGLVKPSETLSLTCTVSGFSLSNYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDYYDYEFAYWGQGTLVTVSS
EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK
na
na
null
null
null
2,022
na
EGFR
TBC
TBC
TBC
TBC
TBC
null
QV QLQE SGPGL V KPSE TLSLTCTV SGF S LSNY DVHWVRQ APGKGL EWLGVIWS GGNTDYNTPF TSRLTISVD TSKN QFSLKLSS VTAADT AVYYCA RALDYYD YEFAYW GQG TLVTVS S
E IVLTQ SPDFQSVTPKE KVTITCR ASQSIGT NIHWYQ QKPDQSP KLLIKYA SESISGIPSRFSGSGSGT DFTLTINS LEAED AA TYYCQ QNNEWPTSFGQGT KLEI K
Bedinvetmab
Canine Whole mAb
G2
Lambda
Approved
Active
EVQLVESGGDLVKPGGSLRLSCVASGFTFSSHGMHWVRQSPGKGLQWVAVINSGGSSTYYTDAVKGRFTISRDNAKNTVYLQMNSLRAEDTAMYYCAKESVGGWEQLVGPHFDYWGQGTLVIVSS
QSVLTQPTSVSGSLGQRVTISCSGSTNNIGILGASWYQLFPGKAPKLLVYGNGNRPSGVPDRFSGADSGDSVTLTITGLQAEDEADYYCQSFDTTLGAHVFGGGTHLTVL
na
na
null
null
null
2,018
2019
Canine NGFB
na
na
Canine lupus familiaris
na
na
(June '22: Corrected FWL1 sequence)
E VQLVE SGGD LV KPGG SLRLSCV ASG FTFS SHG MHWVRQ SPGKG LQWVAVIN SGGSS TYYTD AVKG RFTISR DNAKN TVYLQMN SLRAEDT AMYYCAK ESVGGW EQLV GPHFD Y WGQG TLVIVS S
QSVLTQPT SVS GSLGQ RVTISC SGSTNN IGILGASWYQL FPGKAP KLLVY GNGNRPSGVPDRFSGADSGD SVTLTITG LQAEDEAD YYCQS FDTTLGA HVF GGGT HLTV L
Befovacimab
Whole mAb
G2
Lambda
Phase-II
Active
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMDWVRQAPGKGLEWVSSIRGSRGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLYRYWFDYWGQGTLVTVSS
SYELTQPPSVSVSPGQTARITCSGDNLPKYYAHWYQQKPGQAPVVVIFYDVNRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWWSSTPVFGGGTKLTVL
na
na
null
null
null
2,019
2020
TFPI
na
na
Haemophilia
na
na
null
E VQLVES GGG LV QPGG SLRLSC AASGF TFSS YGM DWVR QAPGKG LEWVSSIR GSRGS TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAED TAVYYCARLYRYWFDY WGQG TLVTVS S
SYELTQPPS VSV SPGQ TARITC SGDNLP KY YAHWYQ QKPGQAP VVVIFYD VNRPSGIPERFSGSNSGN TATLTIS GTQAMDEAD YYCQAWW SSTPVFGGGT KLTV L
Begelomab
Whole mAb
G2b
Kappa
Phase-II/III
Active
QVQLQQSGAELVKPGASVKLSCKASGYTFRSYDINWVRQRPEQGLEWIGWIFPGDGSTKYNEKFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCARWTVVGPGYFDVWGAGTTVTVSS
QIVLTQSPAIMSASPGEKVTITCSASSSVSYMNWFQQKPGTSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISRMEAEDAATYYCQQRSSYPNTFGGGTKLEIK
na
na
null
null
null
2,014
2015
DPP4
ADIENNE
na
Graft-versus-host disease
na
na
null
Q VQLQQ SGA ELV KPGA SVKLSCK ASGY TFRSYDINWVR QRPEQGL EWIGWIF PGDGSTKYNEKFKG KATLTT DKSSS TAYMQLSR LTSEDS AVYFCARWTVV GPGY FDVW GAG TTVTVS S
Q IVLT QSP AIMS ASPGE KVTITCS ASSS VSYMNWF QQKPGTSP KLWIYS TSNLASGVP ARFS GSGSGT SYSLTISR MEAEDA ATYYCQQ RSSYPNTFGGG TKLEI K
Belantamab
Whole mAb ADC
G1
Kappa
Approved
Active
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQAPGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYRKLPWTFGQGTKLEIK
na
na
null
null
null
2,017
2018
TNFRSF17
GlaxoSmithKline
Multiple myeloma
na
na
na
null
Q VQLVQ SGA EVK KPGS SVKVSCK ASGGT F S NYWMHWVR QAPGQG LEWMGATYR GHSDTYYNQKFK GRVTITA DKSTS TAYMELS SLRSEDT AVYYCA RGA IY DG YDVL DNWGQG TLVTVS S
DIQMTQSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KLLIYYT SNLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YRKLPWTFGQGT KLEI K
Belimumab
Whole mAb
G1
Lambda
Approved
Active
QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS
SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL
na
na
5y9k:HL/5y9j:HL/6fxn:OP:QR:MN:FG:HI:DE
null
6erx:HI:DE:QR:MN:FG:OP
2,003
2004
TNFSF13B
Assistance Publique Hopitaux de Paris;Cancer Trials Australia;GlaxoSmithKline;Hospital for Special Surgery;Human Genome Sciences;North Shore-Long Island Jewish Health System;University of Alabama at Birmingham;University of Pennsylvania;University of Wisconsin-Madison;Washington University School of Medicine;Cambridge Antibody Technology
Systemic lupus erythematosus;Lupus nephritis
Anti-neutrophil cytoplasmic antibody-associated vasculitis;Myositis;Emphysema;Membranous glomerulonephritis;Myasthenia gravis;Renal transplant rejection;Systemic scleroderma;Graft-versus-host disease
Waldenstrom's macroglobulinaemia;Rheumatoid arthritis;Sjogren's syndrome
CAT Phage Display
null
Q VQLQQ SGA EVK KPGS SVRVSCK ASGGTFNNN AINWVR QAPGQGL EWM GG IIP MFGTA KY SQNFQG RVAITA DESTG TASMELSS LRSEDT AVYYCA RSRD LLLF PHHALSPWGRG TMVTVS S
SSELTQDPA VSVA LGQ TVRVTC QGDS LR S Y YA SW Y QQKPGQAP VLVIY GKNNRPSGIPDRFSGSSSGN TASLTIT GAQAEDEA DYYCSSR DSSGN HWVF GGGT ELTV L
Belrestotug
Whole mAb
G1
Kappa
Phase-II
Active
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGVIGPSGASTSYAQKFQGRVTLTRDTSTSTVYMELSSLRSEDTAVYYCARDHSDYWSGIMEVWGQGTTVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVRSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYFSPPWTFGGGTKVEIK
na
na
null
null
null
2,022
na
TIGIT
GlaxoSmithKline;iTeos Therapeutics
na
Multiple myeloma;Haematological malignancies;Solid tumours;Non-small cell lung cancer
na
na
null
Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMHWVR QAPGQG LEWMGVI GPSGASTSYA QK FQG RVTLTR DTSTS TVYMELS SLRSEDT AVYYCA RDHSDYW SGIMEVW GQGT TVTVS S
E IVLTQ SPG TLSL SPGE RATLSCR ASQSV RSS YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QYFSPPWTFGGGT KVEI K
Beludavimab
Whole mAb
G1
Kappa
Phase-I/II
Active
QVQLVQSGAEVKKPGASVKVSCKASGYPFTSYGISWVRQAPGQGLEWMGWISTYQGNTNYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYCARDYTRGAWFGESLIGGFDNWGQGTLVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQTVSSTSLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQHDTSLTFGGGTKVEIK
na
na
null
7jx3:AB:CD:HL/6ws6:AB:CD:EF/6wps:CD:FG:HL/6wpt:DE:HL/7bep:HL:GI/7l0n:CD:AB/7r6x:AB/7r6w:AB/7sob:GI:HJ:NO/7soc:HL/7tly:AB;7tm0:JK:LM:NO/7tn0:BA:CD
null
2,021
2022
SARS-CoV-2 Spike RBD
GlaxoSmithKline
na
COVID-19
na
Beludavimab and Sotrovimab have identical Fvs
null
Q VQLVQ SGA EVK KPGA SVKVSCK ASGYPFT SYGISWVRQ APGQGL EWMGWISTY QGNTNY AQKF QG RVTMTT DTSTTT GYMELRRL RSDDT AVYYCAR DYTRGA WF GE SLI GG F DNWGQG TLVTVS S
E IVLTQ SPG TLSL SPGE RATLSCR ASQ TV SST SLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPED FAVYYCQ QHDT SLTF GGG TKVEI K
Bemarituzumab
Whole mAb
G1
Kappa
Phase-III
Active
QVQLVQSGAEVKKPGSSVKVSCKASGYIFTTYNVHWVRQAPGQGLEWIGSIYPDNGDTSYNQNFKGRATITADKSTSTAYMELSSLRSEDTAVYYCARGDFAYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCKASQGVSNDVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQHSTTPYTFGQGTKLEIK
na
na
null
null
7sob:GI:HJ:NO/7soc:HL
2,017
2018
FGFR2
Five Prime Therapeutics;ZAI Lab
na
Gastric cancer
Oesophageal cancer;Solid tumours
POTELLIGENT Technology
null
Q VQLVQ SGA EVK KPGS SVKVSCK ASG YIFTTYNVHWVRQ APGQG LEWIGSI YPDNGDTSYNQNFKG RATITA DKSTS TAYMELS SLRSEDT AVYYCA RGD FAYW GQG TLVTVS S
DI QMT QSPSS LSA SVGD RVTITCK ASQGVSND VAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGT DFTFTIS SLQ PEDIAT YYC QQHSTTPY T FGQGT KLEI K
Bempikibart
Whole mAb
G1
Kappa
TBC
Active
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDHAMHWVRQAPGKGLEWVSGISWNSRGIGYADSVKGRFTIFRDNAKNSLYLQMNSLRAEDTALYYCAKDEYSRGYYVLDVWGQGTTVTVSS
AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLWITFGQGTRLEIK
na
na
null
null
null
2,022
na
IL7R
TBC
TBC
TBC
TBC
TBC
null
E VQLVES GGG LV QPGR SLRLSC AASGF TF DDHA MHWVRQ APGKGL EWVSGISW NSRGI G YADSVKG RFTIFR DNAKN SLYLQMN SLRAEDT ALYYCA KDEYSRG YYVLDV WGQG TTVTVS S
AI QLT QSPSS LSA SVGD RVTITCR ASQG ISSALAWYQ QKPGKAP KLLIYD ASSLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYP LWITF GQGT RLEI K
Benralizumab
Whole mAb
G1
Kappa
Approved
Active
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK
na
na
null
null
null
2,009
2010
IL5RA
AstraZeneca;Cincinnati Children's Hospital Medical Center;Kyowa Hakko;Kyowa Hakko Kirin;McMaster University;MedImmune;National Jewish Medical and Research Center;BioWa
Asthma
Chronic obstructive pulmonary disease;Nasal polyps;Atopic dermatitis;Churg-Strauss syndrome;Hypereosinophilic syndrome;Rhinosinusitis;Eosinophilic gastroenteritis
Skin disorders
POTELLIGENT Technology
null
E VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYVIHWVR QRPGQG LAWMGYI NPYNDGTKYNE RF KG KVTITS DRSTS TVYMELS SLRSED TAVYLC GREGI RYYGLL GDYWGQG TLVTVS S
DIQMTQSPSSL SA SVGD RVTITC GT SEDIINYLNWYQ QKPGKAP KLLIYH TSRLQSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QGY T LP YT FGQGT KVEI K
Bentracimab
Whole mAb
G1
Lambda
Phase-III
Active
QVQLQESGAEVKKPGSSVRVSCKASGGTFDSYSIHWVRQAPGQGLEWMGGIIPAFGTLSSAQDFQARVTISADKSTSTAYMELSGLRSEDTAVYYCARGSFDYYFWSASHPPNDALAIWGQGTLVTVSS
QSVVTQPPSVSAAPGQKVTISCSGSNSDIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQAGDEADYYCGTWLYDRAVGLFGGGTKVTVL
na
na
5alb:HL
null
5alc:HL
2,020
2021
AR-C124910XX
MedImmune;AstraZeneca;PhaseBio
na
Haemorrhage (reversal of effects of ticagrelor)
na
na
null
Q VQLQE SGA EVK KPGS SVRVSCK ASGGTFD SYSIHWVRQ APGQG LEWMGGIIP AFGTLSSAQD FQARVTISA DKSTS TAYMEL SGLRSEDT AVYYC ARGS FDYYFWS ASHPPND ALAIW GQG TLVTVS S
QSV V TQPPSVSAAPGQ KVTISC SGSNSDIGN NYVSWYQQ LPGTAP KLLIY DNNKRPSGIPDRFSGSKSGTS ATLAIT GLQAGDEAD YY CG TWL YDRAVGL FGGGT KVTV L
Benufutamab
Whole mAb
G1
Kappa
Phase-I/II
Active
EVQLQQSGAEVVKPGASVKLSCKASGFNIKDTFIHWVKQAPGQGLEWIGRIDPANTNTKYDPKFQGKATITTDTSSNTAYMELSSLRSEDTAVYYCVRGLYTYYFDYWGQGTLVTVSS
EIVMTQSPATLSVSPGERATLSCRASQSISNNLHWYQQKPGQAPRLLIKFASQSITGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQGNSWPYTFGQGTKLEIK
na
na
6t3j:AB:FG
null
null
2,019
2020
TNFRSF10B
Genmab;VU University Medical Center;iDD Biotech
na
Solid tumours;Multiple myeloma
na
na
null
E VQLQQ SGA EVV KPGA SVKLSCK ASGFNIKD TFIHWVK QAPGQG LEWIGRI DPANTNTKYDPKFQG KATITT DTSSN TAYMELS SLRSEDT AVYYCV RG LYTYYFD YWGQG TLVTVS S
E IVMT QSPA TLSV SPGE RATLSCRA SQSISNN LHWYQ QKPGQAP RLLIKF ASQS ITGI P ARF SGSGSGT EFTLTISS LQSED FAVYYC QQGNSWP YTF GQGT KLEI K
Bepranemab
Whole mAb
G4
Kappa
Phase-II
Active
EVQLQESGPGLVKPSETLSLTCTVSGFSLTSNDIAWIRQPPGKGLEWMGTIWTDGSTNYNTAVQSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARHRLYYGAFDYWGQGTMVTVSS
DIVMTQTPLSLSVTPGQPASISCRSSQSLEYSDGYTYLEWYLQKPGQSPQLLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQATHNPYTFGQGTKLEIK
na
na
null
null
null
2,019
2020
MAPT
UCB BioPharma
na
Progressive supranuclear palsy (PSP);Alzheimer's Disease
na
na
(June '22: Removed duplicate residue from FWL3)
E VQLQE SGPGL V KPSE TLSLTCTV SG FS LTSND IAWIR QPPGKGL EWMGTIWT DGSTNYNTA VQSRVTISVD TSKN QFSLKLSS VTAADT AVYYC ARHR LYYGAFD YWGQG TMVTVS S
DI VMT QTP LSLSV TPGQP ASISCR SSQ SLEY SDGY TYLEWYL QKPGQSP QLLIYEVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYCFQA THNPYTFGQG TKLEI K
Berlimatoxumab
Whole mAb
G1
Kappa
Phase-II
Discontinued
ELQLQESGPGLVKPSETLSLTCTVSGGSISSGSYYWDWIRQPPGKGLEWIGNIYKSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARERGMHYMDVWGKGTTVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQSINSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQQFDPPFTFGGGTKVEIK
na
na
5k59:HL:EF
null
null
2,017
2018
Toxin A
Adimab;Arsanis;X4 Pharmaceuticals
na
na
Staphylococcal infections
na
null
EL QLQE SGPGL V KPSE TLSLTCTV SGGSISSGS YYWDWIR QPPGKGL EWIGNIYK SGS TYY NPSLKS RVTISVD TSKN QFSLKLSS VTAAD T AVYYCA R ERGM HYMDV WGKG TTVTVS S
DIQ MT QSPSS LSA SVGD RVTITCR ASQS INSYLNWYQ QKPGKAP KLLIYAA SSLQSGVPS R FSGSGSGTD FTLTIS SLQ PEDFATYYCQ QQFDPPF T FGGGT KVEI K
Bermekimab
Whole mAb
G1
Kappa
Preregistration
Active
QVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSS
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYEASNLETGVPSRFSGSGSGSDFTLTISSLQPEDFATYYCQQTSSFLLSFGGGTKVEHK
na
na
null
null
null
2,018
2019
IL1A
XBiotech Inc.
na
Colorectal cancer;Cachexia;Atopic dermatitis;Acne vulgaris;Hidradenitis suppurativa;Non-small cell lung cancer;Plaque psoriasis;Systemic scleroderma;Type 2 diabetes mellitus;Vascular restenosis;Pancreatic cancer
Haematological malignancies
na
null
Q VQLVES GGG VV QPGR SLRLSCT ASGF TFSMFGVHWVRQ APGKG LEWVAAVSY DGSNK YYAESV KG RFTISR DNSKN ILFLQM DSLRLEDT AVYYC ARGRP KVVIP APLAHWGQG TLVTF SS
DIQ MT QSPSS VSAS VGD RVTITCR ASQG ISSWLAWY QQKPGKAP KLLIYE ASNLETGVPSRFSGSGSGSD FTLTIS SLQP EDFA TYYC QQTSS FLLSF GGGT KVE HK
Bersanlimab
Whole mAb
G1
Lambda
Phase-II
Discontinued
EVQLLESGGGLVQPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVAFIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYSGWYFDYWGQGTLVTVSS
QSVLTQPPSASGTPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYDNNNRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCQSYDSSLSAWLFGGGTKLTVL
na
na
null
null
null
2,017
2018
ICAM1
BioInvent International
na
na
Multiple myeloma
n-CoDeR
null
E VQLLES GGG LV QPGG SLRLSC AASGF TF SNA WMSWVR QAPGKGL EWVAFIWY DGSNK YYAD SVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCAR YSG WYFD YWGQG TLVTVS S
QSVLTQPPSASGTPGQ RVTISCT GSSSNIGAG YDVHWYQ QLPGTAP KLLIY DNNNRPSGVPDRFSGSKSGTS A SLAI SGLRSEDEA D YYCQ SYDSS LSA WLF GGGT KLTV L
Betifisolimab
Whole mAb
G1
Kappa
Phase-I/II
Active
QVQLVQSGAEVKKPGASVKLSCKASGYIFTTYWMHWVKQRPGQGLEWIGMIQPNSGGTKYNEKFKKKATLTVDKSISTAYMELSRLTSDDTAVYYCARGAGTVDYFDYWGQGSTLTVSS
DIVLTQSPASLAVSVGQRATITCRASESVDIYGNSFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVEAQDTATYYCQQSTEDPYTFGGGTKLEIK
na
na
null
null
null
2,022
na
CD274
MabSpace Biosciences;Transcenta Holding
na
Solid tumours
Haematological malignancies
na
null
Q VQLVQ SGA EVK KPGA SVKLSC KASG YIFTTYWMHWVK QRPGQGL EWIGMI QPNSGGTKYNEKFKK KATLTV DKSI STAYME L S RLTSDDT AVYYCA RGAGT VDYFD YWGQGS TLTVS S
D IVLT QSPA SLAVS VGQ RATITCR ASE SVDIY GNS FMHWYQ QKPGQPP KLLIYRA SNLESGIP ARF SGSGSRT DFTLTIN PVEAQDT ATYYCQQ STEDPYTFGGG TKLEI K
Bevacizumab
Whole mAb
G1
Kappa
Approved
Active
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS
DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK
na
na
1bj1:HL:KJ
null
6bft:AB:HL/1cz8:HL:YX
2,000
2001
VEGFA
All Ireland Cooperative Oncology Research Group;ARCAGY/GINECO Group;Austrian Breast & Colorectal Cancer Study Group;Bayer;Beth Israel Deaconess Medical Center;Breast Cancer Research Foundation;Brigham and Women's Hospital;Bristol-Myers Squibb;Cancer and Leukemia Group B;Cancer Research UK;Chugai Pharmaceutical;Cincinnati Children's Hospital Medical Center;Dana-Farber Cancer Institute;Duke University;European Organisation for Research and Treatment of Cancer;European Thoracic Oncology Platform;Genentech;Hackensack University Medical Center;Hoosier Cancer Research Network;Indiana University School of Medicine;Japan Breast Cancer Research Group;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medical University of South Carolina;Melanoma Research Foundation Breakthrough Consortium;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);National Comprehensive Cancer Network;NCIC Clinical Trials Group;North Central Cancer Treatment Group;NSABP Foundation;Ohio State University Medical Center;Peter MacCallum Cancer Centre;Roche;Royal Marsden NHS Foundation Trust;Sanofi;Sarcoma Alliance for Research through Collaboration;SCRI Development Innovations;South Eastern European Research Oncology Group;Spanish Cooperative Group for Digestive Tumour Therapy;Spanish Lung Cancer Group;Stanford University School of Medicine;SWOG;The Catalan Institute of Oncology;UNICANCER;University College London;University of Alabama at Birmingham;University of Arkansas System;University of California Davis;University of Iowa;University of Oklahoma;University of Tennessee;University of Texas M. D. Anderson Cancer Center;US Oncology Research;West German Study Group;Xijing Hospital
Breast cancer;Cervical cancer;Colorectal cancer;Glioblastoma;Glioma;Non-small cell lung cancer;Ovarian cancer;Renal cell carcinoma;Fallopian tube cancer;Peritoneal cancer
Head and neck cancer;Biliary cancer;Brain metastases;Endometrial cancer;Ewing's sarcoma;Gynaecological cancer;Hodgkin's disease;Intestinal cancer;Liver cancer;Liver metastases;Malignant melanoma;Meningioma;Multiple myeloma;Neuroblastoma;Neurofibromatoses;Rectal cancer;Soft tissue sarcoma;Solid tumours;Urogenital cancer;Neoplastic meningitis;Sarcoma
Carcinoid tumour;Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Eye disorders;Gastric cancer;Gastrointestinal stromal tumours;Mesothelioma;Oesophageal cancer;Pancreatic cancer;Prostate cancer;Small cell lung cancer
na
null
E VQLVES GGG LV QPGG SLRLSC AASGY TFTN YGM NWVRQ APGKGL EWVGWIN TYTGEPT YA ADFKR RFTFSL DTSKS TAYLQMN SLRAEDT AVYYCA KYPHYYGSS HWYFDV WGQG TLVTVS S
DIQMTQSPSS LSA SVGD RVTITCS ASQD ISNYLNWYQ QKPGKAP KVLIYFT SSLHSGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ YSTVPW T FGQGT KVEI K
Bexmarilimab
Whole mAb
G4
Kappa
Phase-I/II
Active
QVTLKESGPTLVKPTQTLTLTCSFSGFSLSTSGMGIGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARHYGYDPYYAMDYWGQGTLVTVSS
EIVLTQSPGTLSLSPGERATLSCTASSSVSSSYLHWYQQKPGKAPKLLIYRTSNLASGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCHQYHRSPPTFGQGTKLEIK
na
na
null
null
null
2,019
2020
STAB1
Faron Pharmaceuticals
na
Solid tumours;Cancer;Immunocompromised infections;Pertussis;Tuberculosis
na
na
null
QV TLK ESGP TLV KPTQ TLTLTCSF SG FSLS TSGM GIGWIR QPPGKA LEWLAHIWW DDDKRYNPALK SRLTIS KDTSKN QVVLTMT NMDPV DTATYYCARH YGYDPY YAMD YWGQG TLVTV SS
E IVLTQ SPG TLSL SPGE RATLSCTA SSSVSSS YLHWYQ QKPGKAP KLLIYRT SNLASGVPS R FSGSGSGTD YTLTISS LQPE DF ATYYCHQ YHRSPPTFGQGT KLEI K
Bezlotoxumab
Whole mAb
G1
Kappa
Approved
NFD
EVQLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIFYPGDSSTRYSPSFQGQVTISADKSVNTAYLQWSSLKASDTAMYYCARRRNWGNAFDIWGQGTMVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSTWTFGQGTKVEIK
na
na
4np4:HL:IM
null
null
2,012
2013
Toxin A
Medarex;University of Massachusetts Medical School;Merck & Co;Merck Sharp & Dohme
Clostridium difficile
na
na
Medarex HuMAb Mouse
null
E VQLVQ SGA EVK KSGE SLKISC KGSGY SFTSYWIGWVRQ MPGKGL EWMGIF YPGDSSTR Y SPSFQG QVTIS ADKSVN TAYLQWSS LKASDT AMYYCAR RRNWGNA FDIW GQG TMVTVS S
E IVLTQ SPG TLSL SPGE RATLSCR ASQSVSS S YLAWYQ QKPGQAP RLLIYG ASSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYC Q QYGSS TWTF GQGT KVEI K
Bifikafusp
Whole mAb Fusion
E
Kappa
Phase-III
Active
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK
na
na
null
null
null
2,010
2011
FN extra domain B
Philogen
na
Non-small cell lung cancer;Diffuse large B-cell lymphoma;[With onfekafusp] Malignant melanoma;[With onfekafusp] Basal cell cancer;[With onfekafusp] Squamous cell cancer;[With onfekafusp] Solid tumours
Malignant melanoma;Renal cell carcinoma;Solid tumours;Atherosclerosis;Head and neck cancer;Pancreatic cancer
na
Radretumab+Bifikafusp+Onfekafusp have identical V domains
E VQLLES GGG LV QPGG SLRLSC AASGF TFSSFSMSWVR QAPGKG LEWVSSIS GSSGT TYYA DSVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCA KPFPYFDYWGQG TLVTVS S
E IVLTQ SPG TLSL SPGE RATLSCR ASQSVS SSFLAWY Q QKPGQAP RLLIYYA SSRATGIPDRFSGSGSGT DFTLTISR LEPE D FAVYYCQ QTGRIPPTFGQGT KVEI K
Bimagrumab
Whole mAb
G1
Lambda
Phase-II
Active
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS
QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL
na
na
5nhr:HL:AB
5nhw:HL/5nh3:HL:IM/5ngv:HL
null
2,012
2013
ACVR2B
MorphoSys;Novartis
na
Cachexia;Muscular atrophy;Type 2 diabetes mellitus
Inclusion body myositis
MorphoSys HuCAL Phage Display
null
Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSSYINWVR QAPGQG LEWMGTI NPVSGSTSY AQKF QG RVTMT RDTS ISTAYMELSR LRSDDT AVYYC ARGG WFDY WGQG TLVTVS S
QSALTQPA SV SGSPGQ SITISCT GTSSDVGS YNYVN WYQ QHPGKAP KLMIYGVS KRPSGVSNRFSGSKSGNT ASLTIS GLQAEDEAD YYC G T FAGGS YYGVF GGGT KLTV L
Bimekizumab
Whole mAb
G1
Kappa
Approved
Active
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYNMAWVRQAPGKGLEWVATITYEGRNTYYRDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASPPQYYEGSIYRLWFAHWGQGTLVTVSS
AIQLTQSPSSLSASVGDRVTITCRADESVRTLMHWYQQKPGKAPKLLIYLVSNSEIGVPDRFSGSGSGTDFRLTISSLQPEDFATYYCQQTWSDPWTFGQGTKVEIK
na
na
null
null
null
2,013
2014
IL17A
UCB
Plaque psoriasis
Ankylosing spondylitis;Psoriatic arthritis;Hidradenitis suppurativa;Ulcerative colitis;Axial spondylarthritis
Psoriasis;Rheumatoid arthritis
na
null
E VQLVES GGG LV QPGG SLRLSC AASGF TF SDY NMAWVRQ APGKG LEWVATITY EGRN TYYRD SVKG RFTISR DNAKNS LYLQMNS LRAEDT AVYYCA SPPQYYEGS IYRLWFAH WGQG TLVTVS S
AI QLT QSPSS LSA SVGD RVTITCR ADE SVRTLMHWYQ QKPGKAP KLLIYLVS NSEIGVPDRFSGSGSGTD FRLTIS SLQPE DFA TYYCQ QTWSDPWTFGQGT KVEI K
Bintrafusp
Whole mAb Fusion
G1
Lambda
Approved
Active
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMMWVRQAPGKGLEWVSSIYPSGGITFYADTVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARIKLGTVTTVDYWGQGTLVTVSS
QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTRVFGTGTKVTVL
na
na
4nki:HL/5grj:HL
null
null
2,015
2016
CD274
AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine
Merkel cell carcinoma;Urogenital cancer
Renal cell carcinoma;Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma
na
Human Phage Display
Avelumab and Bintrafusp have identical V domains
E VQLLES GGG LV QPGG SLRLSCA ASGF TFSSYIMMWVRQ APGKG LEWVSSI YPSGG ITFYAD TVKG RFTISR DNSKN TLYLQMN SLRAEDT AVYYCARIK LGT VTTVDY WGQG TLVTVS S
QSALTQPA SV SGSPGQ SITISCT GTSSDVGG YNYVSWYQ QHPGKAP KLMIYD VSNRPSGVSNRFSGSKSGN TASLTIS GLQAEDEAD YYCSS YTSSST RVF GTGT KVTV L
Birtamimab
Whole mAb
G1
Kappa
Phase-III
Discontinued
EVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMYWIRQAPGKGLEWVARIRSKSNNYAIYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARPYSDSFAYWGQGTLVTVSS
DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSTGNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPFTFGGGTKVEIK
na
na
null
null
null
2,018
2019
SAA1
Neotope Biosciences;Onclave Therapeutics;Prothena
na
na
Amyloid light-chain amyloidosis
na
null
E VQLVES GGG LV QPGG SLRLSC AASGF TFNTYAMYWIRQ APGKG LEWVARIR SKSNN YAIYYA DSVKD RFTISR DDSKNS LYLQMN SLKTEDT AVYYCA RPYSDS FAYW GQG TLVTVS S
DV VMT QSPLSLPVTPGEPA SISC RSSQ SLVH STGNT YLHWYLQ KPGQSP QLLIYKVS NRFSGVPDRFSGSGSGT DFTLKISRVE AEDV GVYYC SQSTHVP FTF GGG TKVEI K
Bleselumab
Whole mAb
G4
Kappa
Phase-II
Discontinued
QLQLQESGPGLLKPSETLSLTCTVSGGSISSPGYYGGWIRQPPGKGLEWIGSIYKSGSTYHNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCTRPVVRYFGWFDPWGQGTLVTVSS
AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPTFGQGTKVEIK
na
na
null
null
null
2,015
2016
CD40
Kirin Brewery;Astellas Pharma;Kyowa Hakko Kirin
na
na
Transplant rejection;Plaque psoriasis;Focal segmental glomerulosclerosis;Renal transplant rejection
na
null
QL QLQE SGPGLLKPSE TLSLTCTV SGGSISSPGY YGGWIR QPPGKGL EWIGSIYK SGSTYHNPSLK SRVTISVD TSKN QFSLKLSS VTAADT AVYYC TRP VVRYFGWF DPWGQG TLVTVS S
AI QLT QSPSS LSA SVGD RVTITCR ASQG ISSALAWYQ QKPGKAP KLLIYD ASNLESGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQQ FNSYPTFGQGT KVEI K
Blinatumomab
Bispecific T-Cell Engager
na;na
Kappa;Kappa
Approved
Active
QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSS
DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIK
DIKLQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS
DIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK
None;None
None;None
None;None
2,008
2009
CD19;CD3E
Amgen;Astellas Pharma;M. D. Anderson Cancer Center;Merck & Co;Micromet Inc;National Cancer Institute (USA);University of California Davis
Precursor B-cell lymphoblastic leukaemia-lymphoma
Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma;Richter's syndrome;Burkitt's lymphoma
Chronic lymphocytic leukaemia
BiTE Technology
null
Q VQLQQ SGA ELV RPGS SVKISCK ASGY AFSS Y WMNWVK QRPGQGL EWIGQI WPGDGDTNYNG KFKGKATLTA DESSS TAYMQLS SLASEDS AVYFCAR RETT T VG RYYYAMD YWGQG TTVTVS S
DI QLT QSPA SLAVS LGQ RATISCK ASQ SV DYDGD SYLNWYQ QIPGQPP KLLIYD ASNL V SGIPPRFSGSGSGTD FTLNIH PVE K VDAA TYHCQ QSTEDPWTFGGG TKLEI K
Blontuvetmab
Canine Whole mAb
G2
Kappa
Unknown
Active
QVQLQQSRAELVRPGASVTLSCKPSGYTFTDYEVHWVKQTPVHGLEWIGAIDPETGGTADNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYCTNFVDVWGTGTTVTVSS
DVVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSGNQKNYLAWYQQKPGQSPRLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVKAEDLAVFYCQQYYNYPLTFGGGTHL
na
na
null
null
null
2,015
2016
MS4A1
Aratana Pharmaceuticals
na
Canine B-cell lymphoma
na
na
null
QV QLQQ S RAELV RPGA SVTLSC KPSGY TF TD YEVHWVK QTPVHG LEWIGAI DPETGGTADNQ KF KG KAILTA DKSSS TAYMELRS LTSEDS AVYYCTNFVDV WGTG TTVTVS S
DV VMS QSPS SLAVS VGE KVTMSC KSSQ SLLY SGNQKN YLAWYQ QKPGQSP RLLIYWA STRESGVPDR F TGSGSGTD FTLTISS VK A E D LAVFYCQQ YYNYPL T FGGGTHL
Blosozumab
Whole mAb
G4
Kappa
Phase-II
Active
QVQLVQSGAEVKKPGASVKVSCKVSGFPIKDTFQHWVRQAPGKGLEWMGWSDPEIGDTEYASKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGDTTYKFDFWGQGTTVTVSS
DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYWASTRWTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSDYPWTFGGGTKVEIK
na
na
null
null
null
2,011
2012
SOST
Eli Lilly
na
Postmenopausal osteoporosis
na
na
null
Q VQLVQ SGA EVK KPGA SVKVSCKV SGFPIKDT FQHWVR QAPGKGL EW MGWSDPEIGDTE YAS KFQG RVTMT EDTSTDT AYMELS SLRSEDT AVYYC ATGDT TYKFDF WGQG TTVTVS S
DIQ MT QSPSS LSA SVGD RVTITCK ASQDV H TAVAWYQ QKPGKAP KLLIYWA STRWTGVPSRFSGSGSGTD FTLTIS SLQ PEDFATYYCQ QYSDYPW T FGGG TKVEI K
Bococizumab
Whole mAb
G2
Kappa
Phase-III
Discontinued
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEISPFGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS
DIQMTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK
na
na
3sqo:HL
null
null
2,013
2014
PCSK9
Halozyme Therapeutics;Pfizer
na
na
Cardiovascular disorders;Hypercholesterolaemia;Hyperlipidaemia
na
null
Q VQLVQ SGA EVK KPGA SVKVSCK ASGY TFTSYYMHWVR QAPGQGL EWMGEI SPFGGRTNYNEKF KSRVTMTR DTSTS TVYMELS SLRSEDT AVYYCA RERPL YA SDLWGQG TTVTVS S
DIQ M TQSPSS LSA SVGD RVTITCR ASQG ISSALAWYQ QKPGKAP KLLIYSASYRY TGVPSRFSGSGSGTD FTFTIS SLQ PEDIATYYCQ QRY SLWRT FGQGT KLEI K
Boserolimab
Whole mAb
G1
Kappa
Phase-II
Active
EIQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTNTGEPTYAEEFKGRFTFTLDTSISTAYMELSSLRSEDTAVYYCAREGDAMDYWGQGTTVTVSS
EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPKRWIYDTSKLASGVPARFSGSGSGTDYSLTISSLEPEDFAVYYCQQWNSYPFTFGQGTKLEIK
na
na
null
null
null
2,022
na
CD27
Bionovion;Merck Sharp & Dohme
na
Non-small cell lung cancer;Small cell lung cancer
Solid tumours
na
null
E IQLVQ SGA EVK KPGA SVKVSCK ASGY TFTN YG MNWVK QAPGQG LKWMGWIN TNTGEPT YAEEF KG RFTFTL DTSI STAYMELS SLRSEDT AVYYCA REGDAMDYWGQG TTVTVS S
E IVLTQ SPA TLSL SPGE RATLSCS ASSS VSYMHWYQ QKPGQAPK RWIYD TSKLASGVP ARFS GSGSGTD YSLTIS SLEPED FAVYYCQ QWNSYPF TF GQGT KLEI K
Botensilimab
Whole mAb
G1
Kappa
Phase-II
Active
EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYAESVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVGLFGPFDIWGQGTLVTVSS
EIVLTQSPGTLSLSPGERATLSCRASQSVSRYLGWYQQKPGQAPRLLIYGASTRATGIPDRFSGSGSGTDFTLTITRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK
na
na
null
null
null
2,020
2021
CTLA4
Agenus
na
Solid tumours
na
na
null
E VQLVES GGG LV KPGG SLRLSC AASGF TFSS Y SMNWVR QAPGKG LEWVSS ISSSSS YIYYAE SVKG RFTISR DNAKNS LYLQMN SLRAEDT AVYYCARV G LF GPF DI WGQG TLVTV SS
E IVLTQ SPG TLSL SPGE RATLSCR ASQS VSRY LGWY QQKPGQAP RLLIYG ASTRATGIPDRFSGSGSGTD FTLTITR LEP ED FAVYYCQ QYGSSPW T FGQGT KVEI K